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Background: A number of lipids function as protective or risk factors in human cognition. Published 
findings are inconsistent and/or insufficient. Few data are available for Asian population. 
 
Objective: To examine the relationship of APOE ε4, PON1 polymorphism and n-3 PUFA and cognition 
(cognitive performance, cognitive decline and dementia) in elderly Chinese Singaporeans. 
 
Methods: The study subjects were recruited from two sources: (1) Chinese participants in the Singapore 
Longitudinal Ageing Study-1 (SLAS-1) and (2) Chinese patients with confirmed diagnosis of dementia from 
Alexandra Hospital. Study I investigated the association of n-3 PUFA supplements intake with cognitive 
decline. Study II investigated the association of n-3 PUFA supplements intake and cognitive performance. 
Study III investigated the association of APOE ε4 allele and dementia. Study IV investigated the PON1 
gene 192Q/R polymorphism and its association with clinical manifestations and disease severity of dementia 
among patients with AD and mixed dementia. Study V investigated the association between PON1 gene 
192Q/R polymorphism and the risk of dementia and the interaction between APOE ε4 status and PON1 gene 
192Q/R polymorphism.  
 
Results: Study I found that daily n-3 PUFA supplements intake was significantly associated with lower risk 
of cognitive decline (adjusted OR=0.23, 95% C.I. 0.07-0.75, P=0.015). Study II showed daily intake of n-3 
PUFA supplements was independently associated with better cognitive performance on memory (β=0.098, 
SE=0.31, P=0.006), executive function (β=0.071, SE=0.43, P=0.046) and information processing speed 
(β=0.074, SE=0.24, P=0.036). Study III showed significant differences in the prevalence of APOE ε4 allele 
between AD patients and cognitively normal controls (35.6% and 17.2% respectively, P =0.005), Odds ratio 
(OR) of the association adjusted for education was 2.41, 95% C.I.1.10-5.28, P=0.028. No significant 
 VIII 
 
association of APOE ε4 allele with VaD/mixed dementia was found. Study IV found that the PON1 R allele 
was significantly associated with more neuropsychiatric symptoms among dementia patients overall. In the 
mixed dementia subgroup, the R allele was significantly associated with three fold increased NPI(S) scores 
(9.01 versus 3.11, P=0.039) and NPI (CD) scores (9.09 versus 2.33, P=0.006), CDR (sum of boxes) score 
(8.57 versus 5.89, P=0.042), GDS/FAST score (4.84 versus 4.11, P=0.007) and BADLS score (6.99 versus 
1.00, P<0.001). Study V showed that the total distribution of PON1 192Q/R genotype was significantly 
different between non-AD dementia and matched controls (29 R/R, 33 Q/R, 4 Q/Q; 32 R/R, 22 Q/R, 12 Q/Q 
respectively, P=0.042), and the presence of at least one R allele (R/R or Q/R) was significantly different 
(93.9 % and 81.8% respectively, P=0.033). Among APOE ε4 non-carriers, the presence of at least one R 
allele (R/R or Q/R) was significantly different between non-AD dementia patients and matched controls 
(95.6% and 80.0% respectively, P=0.024). However, we did not find a significant association between 
PON1 gene 192Q/R polymorphism and the risk of AD/non-AD dementia. 
 
Conclusions:  
These studies indicated that multiple risk and protective factors related to lipid metabolism are involved in 
cognitive decline and dementia. The complex relationships between lipid related factors, cognitive decline 
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CHAPTER 1   INTRODUCTION 
Poor cognitive functioning and dementia are highly prevalent in ageing populations. Because no effective 
cure is available, it is of major importance to identify risk and protective factors in order to prevent cognitive 
decline and delay the onset of dementia. Common known factors include age, gender, ethnicity, education 
level, smoking, use of drug, alcohol consumption, cardiovascular factors (e.g. hypertension, diabetes, heart 
disease and stroke), nutrition (e.g. anti-oxidants and micronutrients), Apolipoprotein (APOE) genotype, 
body mass index (BMI), physical, social and productive activities (1). In particular, several lines of evidence 
suggest that dysregulated lipid metabolism may influence cognitive functioning (e.g. high cholesterol, statin 
use and APOE genotype) (2). The thesis focused on the relationship between APOE ε4, PON1 gene 
polymorphism and n-3 PUFA and cognition (including cognitive performance, cognitive decline and 
dementia) in elderly Chinese Singaporeans. The general background and context of current study is covered 
in Chapter 1. Chapter 2 presented a detailed literature review. 
 
1.1 Population aging 
With rising life expectancy and declining fertility rates, the world’s population is ageing rapidly. It is 
expected that the number of persons aged 65 and above will triple from 524 million in 2010 to 1.5 billion in 
2050 (3-4). In Singapore, one of the fastest ageing populations in Asia, the proportion of residents aged 65 
and above increased from 7.2% in 2000 to 9.3% in 2011 and this will rise to 19% in 2030. Furthermore, by 
2050, Singapore is projected to be the fourth demographically oldest country in the world (5).  
 
1.2 Cognitive decline and dementia in the elderly 
As the elderly population increases, there is growing interest in understanding the changes in cognition 
during the aging process. Neuroscientists generally view the cognitive changes as a continuum from normal 
aging changes to mild cognitive impairment (MCI) to stages of dementia. It has been found that age is the 
most important risk factor for dementia (6-14). Studies have shown that both the prevalence and incidence 
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of dementia double with every five year increase in age. It is estimated that there were 35.6 million people 
living with dementia worldwide in 2010, increasing to 65.7 million by 2030 and 115.4 million by 2050  (15). 
The total number of new cases of dementia each year worldwide is nearly 7.7 million, implying one new 
case every four seconds. In Singapore, the number of demented elderly aged 65 years and above was 22,000 
and will reach 53,000 by 2020 and by 2050 the projected figure will further increase to 187,000 with 
prevalence rate 18.7% (16).  
 
With the high prevalence and incidence worldwide, cognitive decline and dementia in the elderly has 
become a major public health priority. It is associated with a loss of independent function which not only 
affects individuals but also caregivers, family members, the healthcare system and society as a whole. 
 
Dementia is a clinical syndrome characterised by a cluster of symptoms and signs manifested by decline in 
memory, disturbances in language, psychological and psychiatric changes, and impairments in activities of 
daily living (17-18). Late-onset Alzheimer’s disease (AD) and vascular dementia (VaD) are the two leading 
forms of dementia. AD often occurs with VaD, resulting in mixed dementia. AD is widely reported to be 
predominate, and this has also been shown in older (over 70 years) Singaporeans with dementia (where 60% 
were AD cases), but in those aged 50 to 69 years, 65% of dementia cases are VaD (19).  
 
Dementia is one of the main causes of disability in later life. It contributes 11.9% of the years lived with 
disability due to a non-communicable disease; higher than stroke (9.5%), musculoskeletal disorders (2.4%), 
heart disease (5%), and all forms of cancer (2.4%) (20-21). It is also the leading cause of dependency (i.e. 
need for care) and disability among people aged ≥60years in both high-income countries and low- and 
middle-income countries.  
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Dementia has significant social and economic impacts in terms of direct medical costs, direct social care 
costs and the costs of informal care. In 2010, the total estimated global societal costs of dementia were US$ 
604 billion, which corresponds to 1.0% of the aggregated worldwide gross domestic product (GDP), or 0.6% 
if only direct costs are considered (22).  
 
With the large number of people suffering from dementia and the high socio-economic cost of dementia, it is 
overwhelming for the families of affected people and for their caregivers. Physical, emotional and economic 
pressures can cause great stress to families and caregivers, and adequate support is required from the health, 
social, financial and legal systems.  
 
At present, no treatments are available to cure or even alter the progressive course of cognitive decline or 
dementia, although numerous novel therapies are being investigated at various stages of clinical trials.  
Therefore, it is of great importance to identify risk and/or protective factors for potential early prevention 
and intervention.  
 
1.3 Risk and protective factors in cognitive decline and dementia 
Previous research has explored a number of established and putative risk and protective factors for cognitive 
decline and dementia. Some factors are immutable, such as age, gender, ethnicity and APOE ε4 allele. On 
the other hand, some factors are potentially modifiable, e.g. vascular factors (hypertension, type 2 diabetes 
mellitus, stroke, hyperlipidemia), hyperhomocysteinemia, hyperthyroidism, sex hormone levels, depression, 
lifestyle factors (e.g. diet, wine, activity, smoking, exposure to toxins and head trauma), drug exposure (e.g. 
lipid-lowering agents, nonsteroidal anti-inflammatory drugs, benzodiazepines, vaccinations), education and 
occupation (23). In addition, findings from the Singapore Longitudinal Aging Study (SLAS) have suggested 
that dietary intake of foods rich in anti-oxidant or anti-inflammatory phytochemicals present in turmeric or 
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tea were associated with lower risks of cognitive impairment and decline in non-demented Chinese older 
adults (24-25).  
 
1.4 The role of lipids in elderly cognition  
Lipids constitute a broad group of molecules that include fats, waxes, sterols, fat-soluble vitamins (e.g., 
vitamins A, D, E, and K), monoglycerides, diglycerides, triglycerides, phospholipids, and others (26). Their 
biological functions are mainly concerned with energy storage, molecular signaling and as structural 
components of cell membranes (27). There is growing evidence that some lipids (e.g., cholesterol, 
triglycerides, n-3 polyunsaturated fatty acids such as docosahexaenoic acid and eicosapentaenoic acid, and 
apolipoprotein A, C and E) could play roles in cognitive decline of degenerative (AD) or vascular origin 
(VaD) in the elderly population and may be modifiable risk/protective factors (28-30).  
 
Long chain omega-3 polyunsaturated fatty acids (n-3 PUFAs)  
N-3 PUFAs constitute 60% of the membrane fatty acids in neurons. The potential benefits of n-3 PUFAs, 
primarily eicosapentaenoic acid (EPA, C20:5n-3) and docosahexaenoic acid (DHA, C22:6n-3) in slowing 
cognitive decline in non-demented individuals or reducing thre risks of dementia is of great scientific and 
public health interest. Epidemiological studies suggest that n-3 PUFA could be protective against cognitive 
decline or dementia (28, 31-34). However, the evidence is based on limited studies and not unequivocal, 
possibly due to unaccounted sources of n-3 PUFAs and differences in outcome measurement. Dietary 
assessment of fish consumption or total n-3 PUFAs intake are various in different populations according to 
the level and type of fish intake and preparation, and other sources of n-3 PUFAs (35-38). The use of 
supplements is an important source of n-3 PUFAs but no previous observational studies have reported its 
association with cognitive decline, because the use of these supplements was considered to be very low in 
the general population (39). In addition, the screening measurements and criteria that used to define 
cognitive decline and dementia differ between studies. To date, few studies use a full battery of 
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neurocognitive tests, other than the Mini-Mental State Examination (MMSE), to measure cognitive 
performance. This aspect has received scant research attention. 
 
Apolipoprotein E (APOE)  
APOE is a key lipoprotein regulating the transport of cholesterol and the metabolism of lipoprotein particles 
(41-42). The ε4 allele of APOE is the only confirmed genetic risk factor for AD (40). The interaction of 
APOE and the low-density lipoprotein (LDL) receptor determines the homeostasis of cholesterol and 
triglycerides (43-44). However, variability in the strength and type of association between Alzheimer's 
disease and APOE polymorphisms among ethnic groups has been reported. The association of APOE 4 
allele with Alzheimer’s disease or non-AD dementia was weaker for African-Americans than for Hispanics 
and whites, and was not found in native Nigerians, whereas the APOE 2 / 3 genotype was associated with 
an increased risk of AD in African-Americans (45-47). The association of APOE 4 allele with vascular 
dementia (VaD) is still controversial (48). The strength of association of the APOE 4 allele with different 
types of dementia in Singapore is unknown. Genetic polymorphism is therefore linked in a complex way 
with other genetic and environmental risk factors for dementia.  
  
Paraoxonase 1 (PON1)  
APOE ε4 allele is neither necessary nor sufficient for AD (47), implying that other genes may be involved in 
the risk of developing AD. The human paraoxonase 1 (PON1), a potent cholinesterase inhibitor, participates 
in the prevention of LDL peroxidation, which is thought to be the mechanism by which high-density 
lipoprotein (HDL) exerts its anti-atherogenic activity (49-51). At present, there have been inconsistent 
reports of the relationship between the PON1 gene polymorphism at 192 Q/R and AD or VaD risk. Apart 
from three case-control studies conducted in China and Japan (52-54), there have been no other studies in 
Asia on the PON1 gene polymorphism in demented patients. Furthermore, no studies of patients with AD 
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and VaD have examined the effect of PON1 genetic polymorphism on the clinical manifestations and 
disease severity. 
 
1.5 Objectives of the current study 
The thesis focuses on aspects of the relationship between APOE 4, PON1 192Q/R gene polymorphism and 
n-3 PUFA with cognition (including cognitive performance, cognitive decline, and dementia) in elderly 
Chinese Singaporeans. Accordingly, five studies were conducted and the objectives are as follows:  
 
Study I: To examine the association between n-3 PUFA supplements intake and cognitive decline in a 
community-dwelling elderly Chinese Singaporean population without dementia. 
Study II: To examine the association between n-3 PUFA supplements intake and cognitive performance in a 
community-dwelling elderly Chinese Singaporean population without dementia. 
 
Study III: To examine the strength of association between APOE ε4 and dementia in  Singaporean Chinese.  
 
Study IV: To examine PON1 gene 192Q/R polymorphism and its association with clinical manifestations 
and disease severity of Alzheimer’s disease and mixed dementia in Singaporean Chinese. 
 
Study V: To examine (1) the association between PON1 gene 192Q/R polymorphism and dementia and (2) 







   
CHAPTER 2 LITERATURE REVIEW 
2.1 n-3 PUFAs and cognition in the elderly 
The n-3 fatty acids are a class of polyunsaturated fatty acids that includes three nutritionally important types: 
α-linolenic acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (Figure 1).  
 
Figure 1 Chemical structure of ALA, EPA and DHA 
 
 
18:3, n-3; ALA  
 
 
20:5, n-3; EPA 
 
 
22:6, n-3; DHA 
 
On one hand, mammals cannot synthesize ALA so it must be consumed from plant sources such as flax 
seed, canola oil, wheat germ, soyabeans and nuts (e.g. walnuts). In human, ALA is elongated to form EPA 
and DHA, but this conversion is not more than 0.5% (55-56). On the other hand, EPA and DHA are 
predominantly found in fish and seafood, although they can be found in meat and eggs as well.  
2.1.1 Cardiovascular protective mechanisms of n-3 PUFAs 
Biological studies suggest that n-3 fatty acids have protective effects on the cardiovascular system by 
lowering blood pressure, lowering triglyceride (TG) and reducing cardiac death (55). In a meta-analysis of 
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nine prospective studies of incident stroke, there was a dose-response inverse association with increased fish 
consumption (57). Therefore, dietary n-3 PUFAs intake may be protective of VaD through their beneficial 
effects on reducing these cardiovascular risk factors. 
 
2.1.2 Neuroprotective mechanisms of n-3 PUFAs 
The metabolism of ALA, EPA and DHA is different, and epidemiological findings have been inconsistent 
on the protective effects among the different types of n-3 PUFAs (58-59). 
 
Since glucose uptake is impaired in AD and >60% of ALA is β-oxidized, Freemantle proposed that the 
cognitive benefits of ALA could be due to its alternative source of energy via induction of ketogenesis (60-
61). 
 
EPA is thought to be protective by inhibition of the linoleic to arachidonic acid (AA) pathway via 
competition for the same enzymes involved in desaturation and elongation (62). This decreases the 
production of prostaglandins, leukotrienes, and thromboxanes that are activated in AD. 
 
DHA is thought to be the primary neuroprotective n-3 fatty acid in metabolically active brain regions, 
including the cerebral cortex, synaptosomes and mitochondria (63-65). It has been found to increase the 
density of dendritic spines (66-67) and synaptic proteins (66-68), enhance hippocampal neurogenesis (69),  
increase cerebral blood volume (70-71), decrease cholesterol in membranes (72-73), reduce AA and its 
metabolites (59,74), reduce the amyloid-β (Aβ) burden, reduce Aβ40 and Aβ42 levels in the hippocampus 
(75), reduce tau levels, and reduce phosphorylation and conformational changes in tau (74). 
 
2.1.3 Cross-sectional studies 
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To date, nine cross-sectional studies investigated the association between level of n-3 fatty acids (from 
dietary intake, plasma, serum or red blood cells), or fish consumption and dementia, AD, cognitive 
impairment or cognitive performance (76-84). Among the nine studies, three studies examining dietary 
intake of fatty acids or fish oil showed that dietary intake of fatty acids or fish oil could be associated with 
better cognitive performance, and other three studies that examined fish consumption suggested a positive 
association between fish consumption and cognitive performance measured by MMSE or a cognitive test 
battery. Six of the nine studies investigated the relationship of n-3 PUFAs from serum, plasma or 
erythrocytes. Five of these six studies showed that high concentrations of n-3 fatty acids could be associated 
with lower risk of AD, dementia, or better cognitive performance. The other one study from Italy used gas 
chromatography to determine plasma phospholipid fatty acid composition as a marker of the dietary fat 
intake, and suggested that dietary fatty acids are not associated with moderate to severe cognitive 
impairment measured by MMSE. Three of the nine cross-sectional studies measured cognitive function by 
using a cognitive test battery.  In a substudy of the Hordland Health Study (HUSK), a cognitive test battery 
including six tests was performed among 2031 community-dwelling elderly subjects in Western Norway: 
Kendrick Object Learning Test, Trail Making Test (part A), modified versions of the Digit Symbol Test, 
Block Design,  Mini-Mental  State Examination, and Controlled Oral Word Association Test. The findings 
showed that individuals with a diet high in seafood (fish and fish products) had a better cognitive test 
performance on all the cognitive tests compared to those with lower intake of fish and fish products (81). 
Similar results were found by Kalmijn S et al in 2004. In this study, cognitive performance was assessed by 
an comprehensive cognitive test battery that measured memory, psychomotor speed, cognitive flexibility 
and overall cognitive function. Consumptions of both marine omega-3 PUFAs (EPA and DHA) and fatty 
fish were found to be inversely associated with the risk of overall cognitive impairment and psychomotor 
speed (79). In addition, one nested case-control study examined the cognitive performance between fish-oil 
users and food supplement nonusers. The assessment of cognitive performance was covered by a full range 
of cognitive tests including Raven’s Standard Progressive Matrices, the Rey Auditory Verbal Learning Test, 
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the uses of common objects test, and the digit symbol subtest of the Wechsler Adult Intelligence Scale-
revised and the block design subtest of the Wechsler Adult Intelligence Scale-revised. The findings showed 
that, at the age of 64y, compared with fish-oil nonusers, fish-oil users had significantly higher block design 
scores before adjustments for childhood IQ (84). However, In the cross-sectional analysis from 1025 elderly 
men recruited in the Veterans Affairs Normative Aging Study, neither fatty fish intake nor n-3 PUFA was 
found to be associated with cognitive performance that measured by memory/language, speed, and visuo-
spatial/attention. Similarly, in another cross-sectional analysis from Netherlands which included 807 
subjects aged 50-70y, plasma n-3 PUFA concentrations were not associated with any of the performance of 
five tested cognitive domains in terms of memory, sensorimotor speed, complex speed, information-
processing speed and word fluency (109). 
 
Since it is impossible to examine any causal relationship by cross-sectional studies, more literature review 
on prospective studies and clinical trials will be elaborated further in detail. 
 
2.1.4 Prospective cohort studies 
To date, there have been several prospective cohort studies examined the association between fish or 
seafood intake, dietary n-3 PUFAs, or plasma or erythrocyte n-3 PUFAs and dementia, AD, cognitive 
impairment or global cognitive decline. The results have been inconsistent or inconclusive. 
 
Eleven prospective cohort studies examined the relationship between fish intake and dementia, AD or global 
cognitive decline (35, 37-38, 85-92). Among these eleven prospective cohort studies, only one Dutch study 
showed that dietary fish intake was not associated with the risk of dementia. The rest ten studies found 
inverse associations of fish consumption with cognitive function, cognitive decline, AD or dementia (35, 37-
38, 85-88, 90-92). Various species of fish could partially influence the findings. In the Cardiovascular 
Health Cognition Study, Huang TL et al found that consumption of lean fried fish failed to show protective 
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effect on dementia, AD and VaD; however, comparing with subjects who ate fatty fish less than once per 
month, those consumed fatty fish more than twice per week showed a reduced risk of dementia by 28% 
(95% CI: 0.51 to 1.02), and AD by 41% (95% CI: 0.36 to 0.95). In addition, neuroprotective effects of other 
nutrients or their potential interactions should also be considered (93-101).  
 
Seven prospective cohort studies examined the association between dietary n-3 PUFA intake and dementia, 
AD or cognitive decline (36-38, 85, 89, 91-92). In one study including 815 elderly subjects, Morris MC et al 
found that both total dietary intake of n-3 PUFAs and intake of DHA alone were associated with reduced 
risk of incident AD; however, dietary intake of EPA  was not associated with AD (91). The findings on the 
beneficial effect of dietary n-3 PUFAs against AD, dementia or cognitive decline have been inconclusive, 
which could be partially due to methodological differences between studies. Among the two studies using 
cognitive decline as the outcome, one study defined cognitive decline as a drop of more than two points in 
the MMSE scoring over a period of three years (85), whereas the other study used a composite score 
calculated from several cognitive tests as the measurement of global cognitive decline (37). 
 
Nine prospective cohort studies investigated the association of levels of n-3 PUFAs in plasma, serum or 
erythrocyte with AD, dementia, cognitive functioning or cognitive decline (92,100,102-106,108-109). 
Among the six studies that examined total n-3 PUFAs, one study showed that a higher proportion of total n-
3 fatty acids in erythrocyte membranes were associated with a reduced risk of cognitive decline (odds 
ratio=0.59, 95% CI: 0.38,0.93) (106), one study found that total erythrocyte n-3 PUFA concentrations could 
have beneficial effect on cognition from approximately 64 to approximately 68 years old (108), and  one 
study suggested that total plasma n-3 PUFA proportions were associated with less cognitive decline in the 
domains of sensorimotor speed and complex speed (109).  
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Two prospective cohort studies used battery of cognitive tests to assess the cognitive performance among 
the elderly participants. One longitudinal study was based on 404 participants from the placebo arm of the 
FACIT trial. In this study, the cognitive function was measured by five cognitive domains including 
memory, sensorimotor speed, complex speed, information-processing speed, and word fluency. The results 
showed that higher n-3 fatty acid proportions in plasma cholesteryl esters were associated with less decline 
in the cognitive domain of sensorimotor speed and complex speed over 3 years, but were not associated with 
the 3-year cognitive decline in memory, information-processing speed or word fluency test (109). By 
contrast, in the Veterans Affairs Normative Aging Study, after a follow-up period of 6 years, no significant 
associations were found between intake of n-3 PUFAs or fatty fish and the change of any cognitive tests. 
The cognitive tests included memory tests (Word list memory test adapted from CERAD, Backward digit 
span test Wechsler Adult Intelligence Scale-Revised, Pattern memory NES2), language tests (verbal fluency 
CERAD, Boston Naming Test-short form CERAD, Vocabulary Wechsler Adult Intelligence Scale-Revised), 
and tests of perceptual speed and attention (Pattern comparison NES2, Continuous performance test NES2, 
Spatial copying task-constructional praxis CERAD) (258).  
 
2.1.5 Clinical Trials 
To date, findings from several clinical trials have been published. These trials investigated the effects of n-3 
PUFA supplementation on cognitive function in older people. 
 
In the OPAL trial, 867 cognitively healthy elderly subjects aged 70-79 years were randomized into either 
daily capsules (200mg EPA + 500mg DHA) or olive oil for 24 months and the results showed no significant 
differences between active and placebo arms at 24 months in the California Verbal Learning Test (CVLT) 
performance or secondary cognitive outcomes (110). A larger clinical trial from the Netherlands reported the 
effect of four different types of margarines (40 months of daily intake of margarine that provided  400mg 
EPA-DHA, or 2g ALA, or both 400mg EPA-DHA and 2g ALA, or placebo) on the cognitive decline in 
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2911 coronary heart disease patents aged 60-80years. The results showed no effect of n-3 fatty acids on 
global cognitive decline measured by changes in MMSE score (111). Another trial from the Netherlands 
involving 302 cognitively healthy individuals aged ≥65years showed no overall effect of 26 weeks of EPA-
DHA supplementation on cognitive performance (112). In a French population aged 45-80y with a history of 
recent myocardial infarction, unstable angina or ischemic stroke, no significant main effects of group 
assignment on cognitive function were found  (113). On the other hand, in the MIDAS trial from United 
States, 485 subjects aged ≥55 years with defined age-related cognitive decline (ARCD) were randomly 
assigned to 900mg/d of DHA orally or matching placebo (corn oil + soy oil) for 24 weeks. The results 
showed that the 24 week treatment with 900mg/d DHA supplementation was associated with significantly 
fewer PAL six pattern errors (P = 0.03, 95% C.I. (-3.1)-(-0.14)) and better performance on immediate and 
delayed Verbal Recognition Memory scores (P < 0.03) (114). In the OmegAD study from Sweden, 204 
patients with mild to moderate AD were randomly assigned to omega-3 fatty acid-treated group (1.7g/d 
DHA+0.6g/d EPA daily) or placebo (1g of corn oil including 0.6g linoleic acid) for 6 months, followed by6 
months of n-3 PUFA supplementation in all patients. The results showed that there was a significant (P < 
0.05) reduction in MMSE decline rate in a subgroup (n=32) of patients with very mild cognitive dysfunction 
(MMSE score >27) (115). In another study conducted in the United States, the Alzheimer’s Disease 
Cooperative Study randomized 402 individuals (mean age=76y) with mild to moderate AD into either 2g/d 
of  DHA or placebo (corn or soy oil) for a duration of 18 months. Cognitive function was assessed by using 
the cognitive subscale of the Alzheimer’s Disease Assessment Scale (ADAS-cog) and the Clinical Dementia 
Rating (CDR) sum of boxes. A total of 295 participants completed the trial and the findings showed that 
compared with placebo, the use of DHA supplementation did not slow down cognitive decline and 
functional decline in patients with mild to moderate AD (116). 
 
Some of the completed trials used a comprehensive battery of cognitive tests to measure cognitive function. 
One trial showed a protective role of DHA on cognitive performance. In this randomized, double-blinded, 
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placebo-controlled trial, the primary outcome was measured by visuospatial learning and episodic memory 
test (CANTAB PAL), and the secondary outcomes were measured by visual pattern recognition test 
(CANTAB Pattern Recognition Memory, PRM), immediate and delayed verbal memory test (CANTAB 
Verbal Recognition Memory, VRM), executive function test (CANTAB Stockings of Cambridge, SOC), and 
test of temporary spatial retention and search strategy (CANTAB Spatial Working Memory, SWM). The 
results showed that 24-week of 900mg DHA supplementation was significantly associated with better 
performance on CANTAB Paired Associate Learning (PAL) test and higher scores of immediate and 
delayed Verbal Recognition Memory in healthy adults with age-related cognitive decline (ARCD), but not 
working memory or executive function performance (114). On the other hand, two trials failed to show 
protective effects of n-3 PUFA or fish-oil supplementation on cognitive performance in older people. One 
trial showed no change in any of the battery of cognitive tests over 24 months with 200mg EPA plus 500 mg 
DHA daily provided. The primary outcome was a memory test of 16-item word list A from the California 
Verbal Learning Test, CVLT. The secondary outcomes included other memory tests (immediate and delayed 
recalls of a short story from the Wechsler Memory Scale and a spatial memory test), processing-speed tests 
(a letter search and cancellation task, a symbol letter modality test, and measures of simple and choice 
reaction time), executive-function tests (digit span backward from the Wechsler adult intelligence scale and 
verbal fluency of animal naming), and three tests of prospective memory and digit span forward (110). In 
the other trial from the Netherlands, a comprehensive neuropsychological test battery was used to measure 
cognitive performance. The test battery included the cognitive domains of attention, sensorimotor speed, 
memory and executive function. Compared to placebo, neither low-dose nor high-dose fish-oil 
supplementation was associated with any significant changes in any of the domains (112). 
 
Overall, there is lack of definitive conclusion that can support the routine use of n-3 PUFA supplements for 
the prevention, or amelioration, of cognitive decline in the elderly.  
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In summary, unaccounted sources of n-3 PUFA and imprecise measurement may contribute to these 
inconsistent findings. The measurements of n-3 PUFAs were made using dietary consumption of fish in 
eleven observational studies, total dietary n-3 PUFAs in eight studies, plasma or red blood cell n-3 PUFAs 
in nine observational studies, and all seven clinical trials involved taking n-3 PUFA supplements. In the 
Zutphen Elderly study of male elderly aged 70-89 years, a significant association with cognitive decline was 
not observed at 3-year follow-up when only fish consumption was measured, but a subsequent analysis 
which included other dietary sources of n3-PUFA and with 5 years of follow-up found a positive association 
(38). On the other hand, the Chicago Health and Aging Project showed that fish consumption but not the 
intake of n-3 PUFA (from different food items) was associated with less cognitive decline (37).The use of 
supplements is an important source of n-3 PUFA but observational studies have not reported its association 
with cognitive decline, because the use of these supplements was considered to be very low in the general 
population (39). 
 
2.2 APOE and cognition in the elderly 
Human apolipoprotein E(APOE), a class of apolipoprotein, is a 35 kilodalton (kDa) plasma glycoprotein 
consisting of 299 amino acids found in circulating chylomicrons, chylomicrion remnants, very low density 
lipoproteins (VLDLs), intermediate density lipoproteins (IDLs) and high-density lipoproteins (HDLs) (117). 
It is produced predominantly in the liver and, to a small but functionally significant extent, macrophages 
(118-120). At the same time, plasma APOE is expressed in other organs and tissues, including brain, spleen, 
kidneys, lung, ovary, adrenal gland and muscle cells (121). This broad tissue expression suggests that it 
could participate in multiple biological processes.   
 
APOE was originally recognized for its importance in lipid metabolism and cardiovascular disease (117). As 
early as 1981, a mutant form of APOE that is defective in binding to low density lipoprotein receptors 
(LDLRs) was associated with familial type III hyperlipoproteinemia, a genetic disorder characterized by 
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premature atherosclerosis and elevated plasma cholesterol levels (122). The best established role of APOE in 
cholesterol transport is as a ligand for receptor mediated clearance of chylomicron and VLDL remnants. It 
participates in the hepatic clearance of chylomicron remnants and other APOE containing lipoproteins.  
APOE also involves in reverse cholesterol transport (123-124). This dual role of APOE is important for 
clearing the plasma of chylomicron remnants and excess cholesterol. More recently, it has been widely 
linked to several biological functions, both related to and extend beyond lipoprotein transport, including 
immunoregulation (125), oxidative stress (126), cell growth and differentiation, normal brain function and 
neurodegenerative disorders (127-132). In this thesis, we focus on the effects of APOE ε4 allele on cognitive 
function in the elderly adults. 
 
2.2.1 APOE gene polymorphism  
APOE gene is located on the long (q) arm of at chromosome 19 at position 13.2 and consists of four exons 
and three introns spanning 3,597 nucleotides (133-134). The structural gene locus for plasma APOE is 
polymorphic having three major alleles (ε2, ε3 and ε4), coding for three protein isoforms APOE2, APOE3 
and APOE4, respectively. Therefore, three homozygous (ε2/ε2, ε3/ε3 and ε4/ε4) and three heterozygous 
(ε3/ε2, ε4/ε2 and ε4/ε3) genotypes are determined in humans. In the general population, the ε3/ε3 genotype 
is the most common (typically 50-70% of the population), and the ε3 allele accounts for the vast majority of 
the APOE gene pool (typically ~75-80%). The ε4 allele accounts for ~14-15%, and the ε2 allele for ~7-8% 
(135-136).  
 
The molecular basis for APOE polymorphism has been elucidated by amino acid sequence analysis. The 
three protein isoforms (APOE2, APOE3 and APOE4) differ from each other at amino acid substitutions at 
positions 112 and 158. APOE2 has cysteine residues at both positions 112 and 158 (Cys 112, Cys 158), 
whereas APOE4 has arginine residues at both positions (Arg 112, Arg 158). APOE3 has a cysteine residue at 
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position 112 and an arginine residue at position 158 (Cys 112, Arg 158) (137-138). The amino acid 
sequence and structural variations in APOE isoforms have significant functional consequences.  
 
The amino terminal region of APOE is responsible for binding of APOE to LDLR and the carboxyl terminal 
mediates the binding of APOE to surface lipoproteins. The three isoforms differ in their stability, folding 
characteristics, lipoprotein particle preferences, and binding affinities to LDLR and LDLR-related protein 
(LRP). The APOE2 and APOE4 are metabolically different from APOE3. The APOE4 binds selectively to 
triglyceride-rich lipoproteins such as VLDL but APOE3 and APOE4 bind only to HDL. The VLDL-APOE4 
particles are removed faster from plasma than VLDL-APOE3 particles resulting in a downregulation of the 
LDLR. Individuals with the ε2/ε2 genotype have an inefficient catabolism of VLDL clearance which is 
further aggravated by other environmental and genetic factors resulting in type III hyperlipoproteinemia 
(139). 
 
2.2.2 Neurobiological role of APOE  
The importance of APOE in modulating plasma lipid homeostasis is not limited to the peripheral circulation. 
Indeed, an understanding of the critical roles of APOE in the central nervous system (CNS), such as 
neuronal plasticity (140), nerve regeneration (141), neurite outgrowth (142), microtubule stabilization (143) 
and synaptic function (144), is a rapidly emerging field.  
 
APOE is the predominant apolipoprotein in CNS and is primarily expressed by astrocytes (145-146) but also 
by microglia and neurons under diverse physiological and pathological conditions (147-149). Although it is 
present in the same particle along with several other lipoproteins of different size classes in plasma, in the 
CNS, it is secreted by glial cells in unique HDL-like lipoprotein particles (146,150) that are discoidal in 
shape and contain phospholipid and unesterified cholesterol but lack a cholesteryl ester core (151). APOE 
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also exists in cerebrospinal fluid (CSF), in spherical particles that are similar to glial-derived HDL, except 
that they contain a cholesteryl ester core (152).   
 
Within the CNS, the predominance of APOE-containing lipoprotein particles indicates that APOE is critical 
for lipid and cholesterol homeostasis function. In brain tissue, cholesterol is a major lipid component of 
neuronal membranes and myelin sheaths (153) and is essential for normal brain function, e.g. synaptic 
formation (154), dendrite formation (155-156) and axonal growth (157). Cholesterol homeostasis in brain is 
carefully maintained through a series of interdependent pathways, including cholesterol transport in which 
APOE is of vital significance during the membrane remodeling associated with synaptic turnover and 
dendritic reorganization (158-160). APOE may participate in the delivery and clearance of cholesterol and 
phospholipids to neurons and myelin-synthesizing oligodendrocytes. In addition, lines of evidence suggest 
that APOE-containing lipoproteins also play a crucial role in traumatic head injury. In response to nerve 
injury, cholesterol synthesis in neurons is inhibited (161) and neuronal APOE expression is increased (162). 
In the meantime, APOE synthesis in glial cells and lipid transport from glial cells to neurons are both 
increased, thus cholesterol could facilitate repairing the injured cells (163). Studies on isoform-specific 
effects of APOE suggests that APOE3 may be more effective in the repair of cells than APOE4, and APOE4 
displays decreased repair efficiency and could be detrimental in this process (164-166). 
 
2.2.3 APOE and AD  
Alzheimer’s disease (AD) is the most common form of dementia with 20-30 million sufferers worldwide 
(167). It is a progressive neurodegenerative disorder with cognitive dysfunction (memory loss, language 
difficulties and executive dysfunction), non-cognitive symptoms (psychiatric symptoms and behavioral 
disturbances) and difficulties with performing activities of daily living (168). Pathologically, AD is defined 
by the intracellular deposits of hyperphosphorylated tau protein (neurofibrillary tangles) (NFTs), 
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extracellular aggregates of peptide β-amyloid (senile plagues) as well as dystrophic neuritis, gliosis and 
neuroinflammation (169-170). 
 
AD has been classified as early-onset (onset at age <60-65 years) Alzheimer’s disease (EOAD) and late-
onset (onset at age >60-65 years) Alzheimer’s disease (LOAD). It is further genetically divided into two 
forms: Familial Alzheimer’s disease (FAD) and Sporadic Alzheimer’s disease (SAD). Only 5-10% of AD 
cases are early-onset and familial EOAD accounts for <0.1% of all cases of AD, whereas sporadic LOAD is 
more prevalent and represents the majority of total AD cases (171). At present, the APOE genotype is the 
only identified and the most well-established genetic susceptibility factor for developing LOAD, with the ε4 
allele and the ε2 increasing and decreasing the risk, respectively (172-177).  
Experimental evidence has suggested that APOE ε4 allele plays an important role in the pathogenesis of AD. 
As summarized by Huang in 2011, the underlying mechanisms may include enhancing Aβ deposition and 
plague formation, increasing oxidative damage, dysregulation of the neuronal signaling pathways, 
influencing the stability of neuronal cytoskeleton, stimulating tau hyperphosphorylation and formation of 
neurofibrillary tangles, reducing cerebral glucose metabolism, inducing mitochondrial dysfunction and 
impairment of hippocampal GABAergic interneuron (178).  
 
The presence of APOE ε4 allele has been genetically associated with both familial and sporadic late-onset 
AD (143,173). It increases AD risk and decreases mean age at onset in a dose-dependent manner that APOE 
ε4 homozygotes have a higher risk and earlier onset of AD than either APOE ε4 heterozygous individuals or 
APOE ε4 non-carriers (172,176,179). This association has been confirmed in many epidemiological studies 
but the strength of the relationship varies in different populations. In a meta-analysis published in 1997, 
Farrer et al. found that the APOE ε4-AD association was weaker in African Americans and Hispanics but 
stronger among Japanese than Caucasians (45). In addition, a more recent meta-analysis reported that AD 
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patients in Northern Europe have significantly higher frequency of ε4 allele than those in Asia and Southern 
Europe (180).  
 
In Singapore, there have been only a few studies examining the prevalence of APOE ε4 allele in AD patients 
(181-182) and the risk conferring effect of APOE ε4 allele on AD still remains unknown. 
 
2.2.4 APOE and VaD 
Vascular dementia (VaD) is the second most common subtype of dementia after Alzheimer’s disease, 
accounting for 15-20% of all dementias worldwide (183). Moreover, it is estimated that VaD might become 
the most common form of dementia in the elderly (184). In Singapore, it has been reported that VaD was 
predominant among dementia patients aged 60 to 69, although AD was the major entity at older ages (19).  
 
VaD is defined as loss of cognitive function resulting from ischemic, hypoperfusive, or hemorrhagic brain 
lesions due to cerebrovascular disease or cardiovascular pathology (185). It is classified into four subtypes: 
cortical or multi-infarct VaD, subcortical VaD, VaD due to single strategic vascular insults and VaD due to 
generalized severe cerebral hypoperfusion (186). Epidemiological studies have identified several risk factors 
for VaD, including ageing, smoking, sleep apnea, hyperhomocysteinemia, hypertension, diabetes, 
hyperlipidemia, recurrent stroke and cardiac disease (187). Similar to AD, the public healthcare costs of 
VaD increase considerably as the world’s population ages rapidly (188).   
 
In recent years, there is growing evidence that the APOE ε4 allele plays an important role in the 
development of VaD, but its association with VaD risk is still inconclusive (189). A positive association has 
been reported in different populations, e.g. USA, UK, Hungary and Netherlands; however, this association 
has not been consistently replicated in the population of Korea, Belgium, Japan and Finland (190).  
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Only two previous studies assessed the frequency of APOE ε4 allele distribution among VaD patients in 
Singapore (181-182). Additionally, the association of APOE ε4 allele and the risk of VaD is still unclear. 
 
2.3 PON1 gene 192Q/R polymorphism and cognition in the elderly 
APOE ε4 allele has been consistently confirmed as a genetic risk factor for late-onset form of AD; however, 
it is important to note that approximately half of AD patients are APOE ε4 non-carriers (191) and about half 
of APOE ε4 homozygous subjects do not develop AD by the age of 90 (192). Therefore, inheritance of 
APOE ε4 allele is neither necessary nor sufficient to cause AD (193-194). Other environmental and genetic 
factors could also be associated with the development of AD. 
 
2.3.1 PON1 and its biological activities 
The human paraoxonase 1 (PON1) is a serum enzyme that has been extensively investigated in recent years 
for its role in cardiovascular disease, oxidative stress and inflammation (195). It is a Ca
2+
-dependent esterase 
synthesized primarily in the liver and almost exclusively located on the surface of high-density lipoprotein 
(HDL) (50).  
 
PON1 exhibits multiple physiological functions. It protects low density lipoprotein (LDL) from oxidative 
modification, which is thought to be the mechanism by which HDL exerts its anti-atherogenic activity (51). 
Additionally, it is also a potent endogenous cholinesterase inhibitor (ChEI) and an arylesterase that that 
hydrolyzes paraoxon, an active toxic metabolite of parathion, and is thus able to detoxify organophosphates 
and provide neuroprotection against the effects of environmental neurotoxins and age-related 
neurodegeneration (196-197). Several studies have also shown that serum PON1 activity (PON1a) is 
associated with the risk of developing adverse cardiovascular events (198-199). Moreover, PON1a has been 
found to be lower in VaD patients than in healthy control subjects and PON1a might a reliable marker of 
VaD (200). In a recent case-control study, Erlich et al. has proposed that low serum paraoxonase activity is a 
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risk factor for AD (201). Finally, the gene coding for PON1 has been suggested in a meta-analysis as a 
plausible longevity gene for humans (49).   
 
2.3.2 PON1 gene 192 Q/R polymorphism and dementia 
Human serum PON1 enzymatic activity has been reported to display up to 40-fold interethnic variability and 
is genetically determined by a single nucleotide polymorphism (SNP) in the coding region of the PON1 
gene. The PON1 gene is a member of a multi-gene family, including PON1, PON2 and PON3, located on 
chromosome 7q21.3-22.1. The molecular basis of PON1 gene polymorphism is a Gln → Arg substitution at 
residue 192 (NCBI database dbSNP: rs662), that results in three possible genotypes: QQ, QR and RR (202-
204). 
 
PON1 192 Q/R polymorphism is of particular interest to AD and vascular and mixed dementia because of its 
possible effects on dementia pathophysiology and response to cholinesterase inhibition (49, 205).  
Individuals carrying Arg at residue 192 (R allele) reportedly have a higher paraoxon-hydrolyzing activity 
than those carrying Glu (Q allele) (203). Pola et al. demonstrated that subjects carrying the R allele were 
more likely to respond to cholinesterase inhibitor therapy (206). As an endogenous cholinesterase inhibitor 
(ChEI), PON1 may thus augment the biological activity of cholinesterase inhibitor drugs thus improving 
their efficacy.  
 
Late onset Alzheimer’s disease (LOAD) and vascular dementia (VaD) are the two leading forms of 
dementia. AD often occurs with VaD, resulting in mixed dementia. Clinical and epidemiological studies 
suggest that AD and VaD share common risk factors and considerable overlap can be found in their 
pathophysiology, symptomatology and comorbidity (207-208). Neuropsychiatric symptoms are frequently 
observed in about 60 to 75% of patients with dementia (209-210), most commonly apathy (27-36%), 
depression (24-32%) and agitation/aggression (24-30%). They pose enormous burdens of care, but remain 
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poorly understood. At present, the effect of PON1 gene polymorphism on the clinical manifestations and 
severity of dementia is unknown in Singapore. 
 
To date, thirteen case-control studies have observed the relationship between PON1 polymorphism at 192 
Q/R and the risk of developing AD or dementia with inconsistent results. Only two of ten studies in which 
AD patients were selected as cases reported a protective effect of PON1 192 Q/R polymorphism on the risk 
of developing AD (52, 211), and the other eight studies showed a lack of association (53-54, 205, 212-216). 
In three studies which looked into both AD and VaD patients (217-219), one showed that PON1 192 Q/R 
was not significantly associated with AD or VaD (219), one found no significant differences in phenotype 
distribution among AD, VaD and healthy controls (217), and one suggested that the R allele was an 
independent risk factor for vascular and mixed dementia (218).  
 
In Asia, there have been only three case-control studies investigating the association between PON1 192 
Q/R polymorphism and the risk of AD. Of the three studies, one study reported that PON1 R allele might be 
a protective factor for AD in the Chinese population (52), and the other two studies conducted in China and 
Japan failed to find any association between PON1 gene 192 Q/R polymorphism and the risk of developing 
AD (53-54).  
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CHAPTER 3 METHODS 
3.1 Study population 
3.1.1 Community-based: Singapore Longitudinal Aging Study-1 (SLAS-1) 
The Singapore Longitudinal Aging Study (SLAS) is a prospective cohort study of ageing and health among 
community-dwelling older adults in Singapore. In this thesis, the community-based subjects were identified 
from participants of the first wave of SLAS cohort (SLAS-1).  
 
The recruitment of SLAS-1 participants was conducted from among five contiguous districts in South East 
Region of Singapore. Older residents who were Singaporean citizens or permanent residents, aged 55 years 
and above, were identified from a door-to-door census and invited to participate in the study. Subjects were 
excluded if they had severe functional impairment and illnesses that were physically or mentally 
incapacitated to give informed consent or participate, such as those with cancer, stroke, severe hearing, 
visual and speech impairment, and profound dementia. All participants gave signed written informed 
consent for the study, which was approved by the National University of Singapore Institutional Review 
Board.  
 
A total of 2804 eligible residents (Chinese, Malays, Indians and others) participated at baseline from 
September 2003 to December 2005, representing a response rate of 78.5%. All participants underwent an 
extensive series of face-to-face interviews, assessments and tests at baseline, that were performed by trained 
research nurses and psychologists in the on-site study center, in the preferred language or dialect (Chinese or 
English). Baseline information on a wide range of demographic, biological, clinical, psychosocial and 
behavioral variables (220) was collected. Detailed neuropsychological tests were administered at baseline on 
a one-in-three random subsample of the participants who had sufficient visual, language and motor abilities 
that are required to complete the assessments. From March 2005 to September 2007, a total of 1850 
participants completed the first follow-up assessments of the SLAS-1 cohort, at a mean of 1.51 years 
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(SD=0.51) after baseline assessments. Among those who failed to participate in the first follow-up 
examinations, 53 died and 901 were lost to follow-up (444 refused to participate, 15 were unfit to be 
interviewed and 442 could not be contacted). The follow-up of neuropsychological tests were conducted 
among 320 participants, at a mean of 2.64 years (SD=0.60) after the baseline neuropsychological 
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3.1.2 Clinic-based: Memory Clinic of the Department of Geriatric Medicine, Alexandra Hospital  
In this thesis, the patients with clinical diagnosis of dementia were identified from the outpatients in the 
Memory Clinic of the Department of Geriatric Medicine, Alexandra Hospital, between March 1996 and 
April 2009.  
 
The diagnosis of dementia was based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth 
Edition, Text Revision (DSM-IV-TR) (233) and its nosology was established by a multidisciplinary 
consensus approach on the basis of medical history, clinical examination, relevant blood investigations and 
brain imaging with either CT scan or MRI. The National Institute of Neurological and Communicative 
Disorders and Stroke-Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) (234) 
and NINDS-AIREN (235) criteria were used to classify the dementias into AD and VaD, respectively. 
Mixed dementia (AD with cerebrovascular disease) was used to classify patients fulfilling the clinical 
criteria for possible AD and who also presented with clinical or brain imaging evidence of relevant 
cerebrovascular disease.  
 
The research was approved by the Alexandra Hospital’s Ethics Committee and the Domain Specific Review 
Board of the National Healthcare Group. Signed informed consent was provided from the family caregiver 
or a legal representative where applicable. 
 
Data was collected from reviews of case notes, physical and functional assessments, and questionnaire 
interviews upon first diagnosis by the clinicians. Questionnaire interviews containing the instruments of 
Neuropsychiatric Inventory (NPI) and the Bristol Activities of Daily Living (ADL) were uniformly 
administrated for the patients by one trained nurse. Other demographic and clinical variables included 
ethnicity, gender, age, birthplace, education, housing type, history of cardiovascular diseases and risk factors, 
and others. 
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3.2 Study design and Sample size 
3.2.1 Study I: Longitudinal cohort study of the association between n-3 PUFA supplements intake and 
cognitive decline in a community-dwelling elderly Chinese Singaporean population without dementia 
The subjects in the present study were 2611 Chinese participants who were enrolled in the 2004/2005 
baseline examination. In 2005/2006, 1673 participants completed first follow-up examinations, 45 died and 
847 were lost to follow-up (15 were unfit to be interviewed, 444 refused, and 388 could not be contacted). 
After excluding participants with missing data on omega-3 intake (n =10) and participants with probable 
dementia (CDR global score ≥0.5 or IQCODE score ≥3.4, n =188), we studied a final cohort of 1475 
Chinese participants, who completed both at baseline and follow-up assessments (median= 18 months after 
baseline.  Non-participants from loss to follow-up were more likely to be men (P =0.024), had poorer 
baseline cognitive function (P =0.003), and had more depressive symptoms (P =0.004) than subjects who 
were followed up. There were no significant differences in age (P =0.73), education level (P =0.67), and 
proportion of those taking daily supplement of omega-3 (P =0.86). 
 
3.2.2 Study II: Cross-sectional study of the association between n-3 PUFA supplements intake and 
cognitive performance in a community-dwelling elderly Chinese Singaporean population without dementia  
In the current study, data was analysed for 710 non-demented Chinese participants who were examined at 
SLAS-1 baseline and had available data of omega-3 supplements intake and cognitive performance (both 
MMSE and neuropsychological tests). The study was conducted on Chinese elderly subjects only, since 
there were few subjects of other ethnicities (15 Malays, 18 Indians and 6 others). Because demented older 
adults have cognitive impairment and could have changed their n-3 PUFA supplements intake or might give 
imprecise information about their actual food consumption, those with a MMSE score of < 24 (n =86) and 
not fully independent based on the Activity of Daily Living (ADL) scores (n =28) at SLAS-1 baseline were 
excluded for the study. The cutoff of MMSE test performance at 23/24 was supported by a Singapore local 
validation study (222) that MMSE was found to be well discriminated between elderly with and without 
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dementia (cutoff: 23/24, area under the curve: 95%, sensitivity: 97.5%, specificity: 85.2%). Since not all 
subjects completed the whole battery of neuropsychological tests, the number of participants for different 
neuropsychological assessments ranged from to 392 to 664. 
 
3.2.3 Study III: Case-control study of the association between APOE ε4 and dementia in Singaporean 
Chinese 
In this case-control study, a total of 306 Chinese subjects were recruited from two sources: (1) 153 Chinese 
patients with confirmed diagnosis of dementia (87 AD, 19 VaD and 47 mixed dementia) from the Memory 
Clinic of the Department of Geriatric Medicine at Alexandra Hospital, and (2) 153 age- and gender- 
matched “cognitively normal” Chinese participants from the Singapore Longitudinal Ageing Study-1 
(SLAS-1), with ≥26 points on the MMSE total score. 
 
3.2.4 Study IV: Observational study of Paraoxonase 1 (PON1) gene 192Q/R polymorphism and its 
association with clinical manifestations and disease severity of Alzheimer’s disease and mixed dementia in 
Singaporean Chinese  
In this observational study, we analyzed 186 Chinese patients with AD and mixed dementia (109 AD and 77 
mixed dementia) who were outpatients in the Memory Clinic of the Department of Geriatric Medicine in the 
Alexandra Hospital, Singapore.  
 
3.2.5 Study V: Case-control study of the association between Paraoxonase 1 (PON1) gene 192Q/R 
polymorphism and dementia and the interaction between APOE ε4 and PON1 192 Q/R genotypes in 
Singaporean Chinese 




   
3.3 Outcome measurements 
3.3.1 Cognitive performance 
Global cognitive function 
In Study I and Study II, the Mini-Mental State Examination (MMSE) was used to assess the global 
cognitive function on domains of memory, attention, language, praxis and visuo-spatial ability (221). The 
Chinese version of MMSE has been validated for local use among Singaporean older adults (222). The 30 
items were coded as zero if the subjects refused or were unable to complete. Total score of MMSE ranges 
from 0 to 30, with higher score representing better cognitive performance.  
 
Cognitive impairment 
In Study I, cognitive impairment was defined by an MMSE total score of 23 or less, which was previously 
shown to have high sensitivity (95.5%) and specificity (83.5%) for predicting dementia in older Singaporean 
adults (222).  
 
Cognitive decline 
In Study I, cognitive decline was defined as at least 2-point drop in the MMSE test scores between baseline 
and follow-up assessments (35). 
 
Neuropsychological tests 
In Study II, at SLAS-1 baseline, trained research assistants administered a separate standardized battery of 
comprehensive neuropsychological tests, including Digit Span (223), Spatial Span (224), Rey Auditory 
Verbal Learning Test (RAVLT) (225), Visual Reproduction (VR) (224), Categorical Verbal Fluency, 
Design Fluency (226), Symbol Digit Modalities Test (SDMT) (227), Trail Making Test A and B (228) and 
Block Design (223). The assessments were administered in English, Mandarin, or Chinese dialects 
according to the participant’s habitual use. The entire battery took 90-120 minutes to complete. For Study II, 
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we excluded Trail Making Test and Block Design, since these tests were added to the test battery at a later 
stage of the SLAS-1 cohort and the sample sizes were too small (n =197 and 148, respectively) to give 
meaningful results.  
 
Digit Span 
In Digit Span Forward, the research assistant will read lists of digits in sets with progressively increasing 
length, at the rate of 1/second. When the research assistant finishes, the participant is asked to repeat the 
digits in the same order. In Digit Span Backward, the participant is asked to repeat the digits in the 
backwards order.  
 
Spatial Span   
A computerized version of the test was used. In Spatial Span Forward, the participant is asked to touch the 
boxes on the computer screen in the same order in which they flashed. In the Spatial Span Backward, the 
participant is asked to touch the boxes in the backwards order. 
 
Rey Auditory Verbal Learning Test (RAVLT) 
The research assistant will read a list of words to the participant in a series of five trials (Trial 1-5). In each 
trial, when the research assistant finishes, the participant is asked to repeat back as many words as he/she 
can remember in any order. Then the research assistant will read a second list of words and the participant is 
asked to repeat back as many words as he/she can remember (Trial B). Thirty minutes later, the research 
assistant will ask the participant to recall as many words as he/she can remember from the first list (Recall 
A). 
 
Visual Reproduction (VR) 
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The participant will be given 10 seconds to look at each of five cards. Among the five cards, three cards are 
with the same design and the other two cards are with different individual designs. For each card, the 
participant is asked to reproduce them from memory after 10 seconds of observation. Thirty minutes later, 
the participant is asked to reproduce the designs of the five cards again.  
 
Categorical Verbal Fluency 
The participant is asked to name as many words as he/she can in one minute from three categories (Animal, 
Vegetable and Fruit) respectively.  
 
Design Fluency 
The research assistant will instruct the participant to generate different designs in one minute by connecting 
dots with four straight lines, as quickly as he/she can. In condition I, there are only filled (black) dots. In 
condition II, both filled (black) and empty (white) dots are presented and the participant is asked to connect 
only the empty (white) dots. Lastly, in condition III, the participant is asked to switch between filled and 
empty dots.  
 
Symbol Digit Modalities Test (SDMT) 
In the written administration of SDMT, the participant is given a reference key and is required to pair as 
many numbers as he/she can with a series of corresponding geometric symbols and file the numbers in 
boxes. In the oral administration of SDMT, the research assistant will record the numbers spoken by the 
participant. The entire test should be finished in 90 seconds. 
 
All raw test scores were converted into standardized Z scores, which were summed to construct 4 composite 
cognitive domain scores: Attention score=Sum of (Zdigit span forward longest span, Zdigit span backward longest span, Zspatial span 
forward longest span, Zspatial span backward longest span); Memory score=Sum of (ZRAVLT immediate recall, ZRAVLT delayed recall, 
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ZVisual Reproduction immediate recall, ZVisual Reproduction delayed recall); Executive Function score= Sum of (Zcategorical verbal 
fluency, ZDesign Fluency condition 1, ZDesign Fluency condition 2, ZDesign Fluency condition 3); Information Processing Speed score = 
Sum of (ZSDMT written version, ZSDMT oral version). 
 
3.3.2 Clinical manifestations and disease severity of dementia 
In Study IV, clinical manifestations and severity of dementia were measured among the demented patients. 
 
Cognitive status was assessed using the Mini-Mental State Examination (MMSE). A locally validated 
Singapore version (222) was used to determine global cognitive function based on domains of memory, 
attention, language, praxis and visual-spatial ability; with summed scores ranging from 0 to 30, higher 
values denoting better cognitive performance. 
 
Global rating scales utilized in assessment of patients included the Clinical Dementia Rating (CDR) (236-
237) and the Global Deterioration Scale (GDS) (238).The CDR clinically stages the severity of dementia by 
assessing domains of memory, orientation, judgment and problem-solving, community affairs, home and 
hobbies, and personal care; with global score [CDR(Global)] ranging from 0 to 3 and sum of boxes 
[CDR(SOB)] score ranging from 0 to 18. Higher scores on the CDR denote later stages and greater severity 
of dementia. The GDS provides caregivers and clinicians with an overview of the stages of cognitive 
function for those suffering from a primary degenerative dementia such as AD. It has 7 seven stages of 
which 1-3 are pre-dementia stages and 4-7 are dementia stages.  
 
Neuropsychiatric symptoms were evaluated by using the Neuropsychiatric Inventory Questionnaire (NPI-Q) 
(239), a brief clinical form of the Neuropsychiatric Inventory (NPI) (240), which had previously been 
validated and highly correlated with NPI and found to be useful in clinical practice. NPI-Q is made up of 12 
symptom domains derived from the original NPI. Neuropsychiatric symptoms are assessed on a 3 point scale 
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for each symptom domain and the total NPI severity score, NPI-Q(S), represents the sum of individual 
symptom scores and ranges from 0-36. Caregiver distress associated with the symptoms is anchored on a 0-5 
point scale; the total NPI-Q distress score, NPI-Q(CD), represents the sum of the individual distress scores 
and ranges from 0-60.   
 
Physical functional status was defined by the Bristol Activities of Daily Living Scale (BADLS) (241), a 20-
item carer-rating instrument specifically designed for dementia patients, giving a total score range of 0 to 60, 
lower scores indicating better daily function. Functional assessment staging (FAST) (243) was also utilized 
in evaluating the functional deterioration of AD and mixed dementia patients during the course of their 
illness. As a functional ordinal scale (244), it consists of 1 (no disability) to 7 (highest level of disability) 
with information based on caregiver input. 
 
3.3.3 Omega-3 intake  
In Study I and Study II, information about habitual intake of omega-3 supplements was determined using a 
single question, “For the past 12 months, do you regularly consume omega-3 supplements?” The responses 
was measured on a 5-point Likert scale: 1 =Never or rarely; 2 =Occasionally (Less than 1 time a month); 3 
=often (More than 1 time a month but less than 1 time a week); 4 =Very often (More than 1 time a week but 
not daily); 5 =Always (Daily). Because the responses were extremely bimodal in their distribution, with less 
than 5% in the intermediate frequencies of intake, they categorized into daily and less-than-daily 
consumptions. Respondents were considered to be daily consumers of n-3 PUFA supplements if they 
reported daily consumption of omega-3 supplements, and were able to produce the supplements to the 
research nurse interviewer for verification. Included under the family of omega-3 fatty acids were α-
linolenic acid (ALA; 18:3ω-3), docosahexanoic acid (DHA; 22:6ω-3) and eicosapentanoic acid (EPA; 
20:5ω-3).   
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3.3.4 APOE and PON1 genotyping 
APOE genotyping  
For Study III and Study V, the DNA extraction was carried out using QIAamp DNA blood Midi kits 
(Qiagen, Hilden Germany) following the manufacturer’s recommended protocol. APOE genotyping was 
carried out by determining the genotype at two polymorphic sites in codons 112 and 158 of the APOE locus. 
ε2 allele contains a cysteine at position 158 and ε4 contains an arginine at 112. 
  
A DNA fragment encompassing both polymorphisms was amplified by polymerase chain reaction (PCR) 
using the primers  
5’-ATGGACGACCATGAAGGAGTTGAA-3’ and   
5’-ACGCGGCCCTGTTCCACCAG-3’ . 
 
PCR amplification was carried out in a 10ml reaction volume containing 0.1mmol/l of each dNTP, 
1.5mmol/L magnesium chloride, 0.41mmmol/l of each primer and 0.06U of Qiagen Hotstar Taq polymerase. 
PCR cycling conditions would be 95° C for 30 seconds, 65° C for 30 seconds and 72°C for 40 seconds. A 
final extension phase for 5 minutes at 72°C was included at the end of the protocol. PCR products were 
incubated for 90 minutes at 37°C followed by 15 minutes at 75°C (to inactivate the enzymes) with 5U each 
of EXO I and calf intestinal phosphatase (New England Biolabs) to remove on-incorporated primers and 
dNTPs. 
 
Subsequently, genotyping was carried out using Single Nucleotide extension using ABI Prism SnaPshot 
multiplex system (Applied Biosystems, CA) and the following probes: 
1. codon 112--AAA AAA AAA AAA AAA AAA GCG GAC ATG GAG GAC GTG 
2. codon 158--AAA AAA AAA AAA AAA AAA AGC CGA TGA CCT GCA GAA G 
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The extension reaction was carried in a reaction reagent that contains snapshot ready reagent mastermix, 
water, mixed PCR products and probes. These were placed in a PCR thermocycler for 35 cycles for 96°C for 
30 seconds, 50°C for 30 seconds and 60°C for 30 seconds. The final products were then be electrophoresed 
on an ABI Priism 3100 genetic analyzer (Applied Biosystems). Genotyping were carried out using 
Genotyper version 3.7 (Applied Biosystems). 
 
The APOE genotypes were classified into ε2/ε2, ε2/ε3, ε3/ ε3, ε2/ ε4, ε3/ε4, and ε4/ ε4. Participants with the 
APOE ε4 allele (ε2/ ε4, ε3/ ε4, and ε4/ ε4) were classified as APOE ε4 carriers and those without it (ε2/ ε2, 
ε2/ ε3, and ε3/ ε3) as APOE ε4 non-carriers. 
 
PON1 genotyping 
For Study IV and Study V, whole blood deoxyribonucleic acid (DNA) was extracted using commercial 
column (Qiagen-QIAamp DNA Blood mini kit). Real time polymerase chain reaction (PCR) was used for 
genotyping of SNP rs662 (chromosome 7) (Applied Biosystems, TaqMan Pre-Designed SNP Genotyping 
Assay). 
 
The TaqMan SNP genotyping assay allows genotyping of the two possible variants at the single SNP site in 
a target template sequence. In each assay, there are two Taqman® MGB probes and each contains a 
fluorescent reported dye (one to the wild-type, and the other to the mutation). The allelic discrimination 
assay classified samples as Homozygotes (samples with only allele 1 or 2) and Heterozygotes (samples with 
both alleles). TaqMan® MGB probe for rs662 SNP (labelled with VIC® / Fam® dye) was used:  
(20X)TAAACCCAAATACATCTCCCAGGAT[C/T]GTAAGTAGGGGTCAAGAAAATAGTG  
Based on Glycine (Gln) [for Q allozyme] -> Arginine (Arg) [for R allozyme] substitutions at residue 192, 
three genotypes are derived: QQ, QR and RR.  
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3.3.5 Covariates 
In the thesis, related SLAS-1 baseline data were collected for analysis.  
 
The information included age (in years), gender and education (in years), 
smoking (current smoker versus ex-smoker or non-smoker), alcohol drinking (at least one alcoholic drink 
daily or less), vegetables and fruit consumption (at least one serving everyday), fish consumption (more than 
3 times a week), and coffee consumption (more than one cup a day or less). Leisure-time activities were 
assessed by questioning on the number and frequency of the respondents’ usual participation in 16 different 
categories of physical, social or productive activities, which are commonly performed by local older adults 
during their leisure times (245). The composite scores, with higher scores representing increasing levels of 
participation, were computed from the number and frequency of participation for all categories of activities 
(maximum score=32), and divided into tertile categories (low=less than 8, medium=8 to11, high=12 or 
more). A 10-item NSI-DETERMINE checklist was used to measure general nutritional status. The weighted 
cumulative score ranged between 0 and 21, with scores of 3 and above were indicative of nutritional risk 
(229). Information on chronic medical conditions was ascertained using self-reports of physician diagnoses 
and cardiac procedures and surgeries, interviewer inspection of all medications currently taken, and 
measurements of blood pressure, ECG, fasting blood glucose and lipids. This included vascular diseases and 
risk factors (hypertension, diabetes, ischemic heart disease, congestive heart failure, atrial fibrillation, and 
stroke), asthma, chronic obstructive pulmonary disease (COPD), major eye disorders (cataract, glaucoma, 
etc), arthritis, thyroid and gastric problems. Comorbidity was classified by the total number of chronic 
conditions for each participant. The presence of depressive symptoms in the past week was determined by 
the locally validated Chinese version (230) of the 15-item Geriatric Depression Scale (GDS) (231), with the 
total score ranging from 0 (no depressive symptoms) to 15 (severe depressive symptoms). The GDS-15 has 
been found to be reliable in screening major depressive disorder with overall sensitivity of 0.97 and 
specificity of 0.95, without clinically significant differences in test performance among different age, gender, 
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ethnicity and comorbidities at cutoff of 4/5. Participants with summed scores of 5 and above were 
considered to have depressive symptoms (232). Physical functioning was assessed by the participant’s level 
of dependency in performing basic activities of daily living (BADL) (241) and instrumental activities of 
daily living (IADL) (242). Functional dependence was defined as needing personal help in at least one 
BADL or IADL tasks. Height and weight was measured by using a portable Seca stadiometer (Model 708, 
Vogel&Hake Hamburg, Germany), with the body mass index (BMI) calculated as kg/m2.  
 
3.4 Statistical analysis 
3.4.1 Study I: Longitudinal cohort study of the association between n-3 PUFA supplements intake and 
cognitive decline in a community-dwelling elderly Chinese Singaporean population without dementia 
Differences in baseline characteristics and cognitive impairment and cognitive decline between respondents 
who consumed omega-3 daily and less than daily were evaluated using independent T-test for continuous 
variables and Chi-squared trend tests for categorical variables. Multivariate analyses of the associations 
between omega-3 intake and cognitive decline were performed using binomial logistic regression models 
controlling for relevant confounding variables. The covariates included age (single years), education (0-6 
years or more), gender, presence of vascular risk factors/ diseases, number of medical comorbidities (none, 
1-2, 3+), depressive symptoms (GDS≥5 or less), level of leisure-time activities (low, <8; medium, 8-11; high, 
≥12), smoking, alcohol drinking, nutritional status (NSI ≥5 or less), APOE status, length of follow up and 
baseline MMSE score. To reduce reporting bias due to impaired cognitive functioning, we re-analyzed the 
data after excluding participants with MMSE score <24 at baseline to examine whether omega-3 intake 
remained associated with cognitive decline. Because of the increased probability that persons with a history 
of cardiometabolic diseases (coronary heart diseases, cardiac failure, stroke, and diabetes) might alter their 
habitual consumption of omega-3 supplement, we also reanalyzed the relationship after excluding these 
participants in the analysis. Odds ratios (ORs) of associations were computed yielding point estimates with 
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95% confidence intervals (95% CI). All analyses were carried out with SPSS statistical software version 
15.0 (SPSS, Inc., Chicago, Illinois). A 2-sided P value of less than 0.05 was considered significant.  
 
3.4.2 Study II: Cross-sectional study of the association between n-3 PUFA supplements intake and 
cognitive performance in a community-dwelling elderly Chinese Singaporean population without dementia 
In univariate analyses, baseline characteristics were compared between omega-3 supplements’ daily users 
and less-than-daily users, using the independent t-test for continuous variables and chi-square test for 
categorical variables. Multivariate analyses of the cross-sectional association between omega-3 supplements 
intake and cognitive performance were performed using binomial logistic regression that controlled for 
relevant confounding variables. The base model (model 1) included n-3 PUFA supplements intake (daily 
and less-than-daily) as the sole variable. Additional covariates were added to subsequent models: age, 
gender and education (model 2); smoking, alcohol consumption, BMI, hypertension, diabetes mellitus, 
stroke, heart disease, depressive symptoms, APOE ε4, level of leisure-time activities, vegetables and fruits 
consumption, fish consumption and coffee consumption (model 3). The level of statistical significance was 
set at P <0.05 with two-tailed distribution. All statistical analyses were carried out using SPSS statistical 
software (version 15.0; SPSS, Inc., Chicago, IL). 
 
3.4.3 Study III: Case-control study of the association between APOE ε4 and dementia in Singaporean 
Chinese 
Data were analyzed with independent t-test for continuous variables and chi-square test for categorical 
variables. Allelic frequencies of APOE ε4 were compared between dementia cases and controls using the 
chi-square test. Odds ratios (ORs) of the association between APOE ε4 allele status and dementia were 
calculated in conditional logistic regression models adjusted for education. Two-sided P value of less than 
0.05 was considered to be statistically significant. All analyses were conducted using SPSS statistical 
software version 15.0 (SPSS, Inc., Chicago, Illinois).  
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3.4.4 Study IV: Observational study of Paraoxonase 1 (PON1) gene 192Q/R polymorphism and its 
association with clinical manifestations and disease severity of Alzheimer’s disease and mixed dementia in 
Singaporean Chinese 
Data were analyzed with independent t-test for continuous variables and chi-square test for categorical 
variables. The Hardy-Weinberg equilibrium was confirmed for all patients. Allelic frequencies were 
estimated by the allele counting method. Genotypes and allele frequencies were compared by chi-square test. 
A two-sided P value of less than 0.05 was considered significant. All analyses were conducted using SPSS 
statistical software version 15.0 (SPSS, Inc., Chicago, Illinois).  
 
3.4.5 Study V: Case-control study of the association between Paraoxonase 1 (PON1) gene 192Q/R 
polymorphism and dementia and the interaction between APOE ε4 and PON1 192 Q/R genotypes in 
Singaporean Chinese 
Data were analyzed with independent t-test for continuous variables and chi-square test for categorical 
variables. The Hardy-Weinberg equilibrium was verified for both demented patients and cognitively normal 
controls. Allelic frequencies were estimated by the allele counting method. PON1 genotype distribution and 
allele frequencies between dementia and controls were compared by chi-square test. Odds ratios (ORs) of 
the association between PON1 gene 192 Q/R polymorphism and dementia were calculated in conditional 
logistic regression models adjusted for education and APOE ε4 status. Interactions between APOE ε4 allele 
and PON1 genotypes were tested by logistic regression. All analyses were conducted using SPSS statistical 






   
CHAPTER 4 RESULTS AND DISCUSSION 
4.1 Study I 
4.1.1 Results  
We found that 90 (6%) of the participants were daily n3-PUFA supplements consumers (Table 1). 
Compared with those who consumed n3-PUFA less-than-daily, those who consumed n3-PUFA daily were 
younger (P=0.029), and showed shorter length of follow-up (P=0.011), more years of education (P<0.001), 
higher level of leisure-time activities (P=0.006), higher baseline MMSE score (P<0.001), less cognitive 
impairment at baseline (P=0.035), but otherwise did not differ significantly in gender, number of medical 
comorbidities, presence of vascular risk factors/diseases, APOE status, smoking, alcohol drinking, 
nutritional status, frequency of fish intake, or number of depressive symptoms. Daily consumers of n3-
PUFA compared to non-consumers showed higher mean MMSE scores at baseline (mean 28.2 versus 27.0, 
P<0.001), fewer cases of cognitive impairment (4.4% versus 11.7%, P=0.035) at baseline, and less cognitive 
decline at follow-up (15.9% versus 6.7%, respectively; P=0.019). 
  
The odds ratio estimated in univariate analysis for the association of daily intake of omega-3 supplements 
with cognitive decline was 0.38 (95% CI 0.16-0.88) (Table 2). In multivariate analyses, the estimated OR 
remained significantly low after controlling for possible confounding by age, gender, education, number of 
medical comorbidity, hypertension, diabetes, cardiac diseases, stroke, smoking, alcohol drinking, 
depression, APOE ε4 status, nutritional status, level of leisure activity, baseline MMSE and length of follow-
up (OR=0.37), and after excluding participants with cognitive impairment (MMSE<24) at baseline 
(OR=0.36), and additionally those with DM, stroke, and cardiac diseases (OR=0.23). 
 
We found no statistically significant association (OR=1.02, 95% CI 0.81-1.27) of fish consumption (3 or 
more times a week) with cognitive decline. 
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Table 1 Baseline characteristics of study participants  
 




No (n=1385) Yes (n=90) 
    
Length of follow-up, yr (mean/ SD) 1.58 (0.50) 1.45 (0.42) 0.011 
Age, yr (mean/ SD) 66.2 (7.5) 64.4 (6.6) 0.029 
Female 65.8% 64.4% 0.80 
Education: 6 yrs or less 55.1% 28.9% <0.001 
Number of medical illness    
   None 8.7% 7.8% 
0.91    1-2 49.0% 51.1% 
   3+ 42.4% 41.1% 
Vascular risk factors/ diseases    
Hypertension 55.6% 54.4% 0.83 
Diabetes 17.0% 10.0% 0.085 
Cardiac diseases
b
 7.6% 8.9% 0.65 
Stroke 3.8% 4.4% 0.74 
APOE-ε4 carrier 18.2% 19.1% 0.83 
Current smoker 5.6% 5.6% 0.99 
Alcohol drinking 7.5% 7.8% 0.93 
Level of leisure-time activities    
   Low (score <8) 34.0% 17.8% 
0.006    Moderate (score 8-11) 35.6% 43.3% 
   High (score >11) 30.4% 38.9% 
Nutritional risk (Nutrition Screening score ≥3) 30.8% 33.3% 0.62 
Fish consumption (>3 times a week) 49.3% 47.8% 0.78 
Depression (GDS≥5) 11.8% 14.4% 0.45 
MMSE score (mean/ SD) 27.0 (3.4) 28.2 (2.4) <0.001 
Cognitive impairment at baseline 11.7% 4.4% 0.035 
Cognitive decline at follow-up 15.9% 6.7% 0.019 
    
 
a
 Independent sample t test for continuous variables, chi-square test for categorical variables 
 
b 
Ischaemic heart disease or congestive heart failure or atrial fibrillation.
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           Table 2 Association between daily intake of omega-3 PUFA supplements and cognitive decline
a 
 
Logistic Regression Model OR [95% CI]
b
 P-Value 
   
Unadjusted 0.38 (0.16-0.88) 0.023 
Adjusted 
c
 0.37 (0.16-0.87) 0.024
 
Excluding respondents with cognitive impairment (MMSE<24) at baseline 
c
 0.36 (0.15-0.85) 0.020 
Excluding respondents with cognitive impairment, diabetes, stroke, and cardiac diseases 
c
  0.23 (0.07-0.75) 0.015 
  
a 
Cognitive decline: a minimum of 2-point drop in MMSE during follow-up period. 
                  b 
Odds Ratio and 95% Confidence Interval OR [95%CI]. 
c 
Adjusted for: age, gender, education, number of medical comorbidity, the presence of vascular risk factors/diseases, smoking, alcohol  
drinking, depression, APOE status (ε4 allele carriers vs. non-carriers), nutritional status, level of leisure activities, baseline MMSE and 
length of follow-up.
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4.1.2 Discussion 
These results based on a large population study of community-living Chinese elderly aged ≥55y support 
previous observational findings based on dietary intake of n3-PUFA (either from fish and/or other food 
items) suggesting that omega-3 PUFA reduces the risk of cognitive decline in elderly individuals without 
dementia.  
 
No previous observational studies have reported findings for an association of n3-PUFA supplements with 
cognitive decline. To date, all clinical trials which evaluated the use of EHA, EPA or other forms of omega-
3 fatty acids in the form of supplements have failed to provide conclusive evidence that they slow cognitive 
decline in Alzheimer disease patients. However, in a trial which included 174 subjects with mild to moderate 
AD, a reduction in cognitive decline rate was observed in a small subgroup of dementia patients with the 
mildest cognitive impairment (115). Our observational study for the first time demonstrates a reduced risk of 
cognitive decline associated with the use of n3-PUFA supplements. Taken together with previous findings 
(112), the evidence therefore suggests that n-3 PUFAs supplements may be beneficial in the primary 
prevention of cognitive decline.  
 
The neuroprotective effect of n-3 PUFAs is well supported by biological evidence from experimental 
studies.  It has been suggested that both EPA and DHA could reduce cardiovascular risk factors and improve 
cerebral blood flow, reduce inflammation, and directly limit Alzheimer disease (AD) pathology. Long chain 
n-3 PUFAs play key roles in brain development, synaptic plasticity and neurotransmission. They provide 
protection against cardiovascular events by lowering blood triacylglycerols, improving platelet aggregation 
and endothelial function, and being antiarrhythmia. Furthermore, the n-3 PUFAs attenuate inflammation by 
inhibiting the synthesis of proinflammatory cytokines. Given that high levels of inflammation, possibly due 
to β-amyloid peptides, could contribute to cognitive decline, omega-3 fatty acids could have neuroprotective 
effects through their anti-inflammatory properties. Omega-3 fatty acids have been found to increase the 
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density of dendritic spines (66-67) and synaptic proteins (66-68), enhance hippocampal neurogenesis 
(69),increase cerebral blood volume (70-71), decrease cholesterol in membranes (72-73), reduce AA and its 
metabolites (59,74), reduce the amyloid-β (Aβ) burden, reduce Aβ40 and Aβ42 levels in the hippocampus 
(75), reduce tau levels, and reduce phosphorylation and conformational changes in tau (74). 
 
Factors such as education, levels of leisure time activities, and cardiovascular factors have been shown in 
this study population (219, 245-246) and others to strongly influence the likelihood of cognitive decline, and 
were possible confounders in this study. Daily consumers of n3-PUFA supplements were younger, better 
educated and engaged more frequently in leisure time activities, and had better cognitive function at 
baseline. The confounding influence of these related factors were excluded by multivariate analyses that 
controlled for the confounding variables and demonstrated an independent inverse association between n3-
PUFA and cognitive decline. There was the possibility of the results being biased by the inclusion of 
individuals with cognitive impairment at baseline, since they could have changed their dietary intakes or 
might give imprecise information about their actual food consumption. To reduce this reporting bias, we 
excluded participants with MMSE score<24 at baseline and found that omega-3 supplement intake remained 
independently associated with cognitive decline. Similarly, because of the increased probability that persons 
with cardiac diseases, stroke and diabetes may alter their habitual consumption of omega-3 supplement, we 
also re-estimated the odds ratio after eliminating these individuals and found that the association remained 
significant. Other strengths of the present study include its longitudinal population-based design.  
 
However, there are some limitations. First, the analysis was based on a relative small number of omega-3 
supplements daily users (n=90). Although the sample size could be large enough to produce a sufficient 
statistical power, the results should be interpreted cautiously. Further studies with more participants could 
reach an adequate power to provide firmer evidence. Second, selection bias due to death and lost-to-follow-
up could have influenced the results. However, that bias would probably have led to an underestimation of 
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the strength of the associations, because the elderly who dropped out of the present study had lower baseline 
cognitive test scores (P=0.003) and had more depressive symptoms (P=0.004) than subjects who were 
followed up. Third, in this study, cognitive decline was defined by changes in MMSE between baseline and 
follow-up assessments. Therefore, our findings did not provide data of declines in specific cognitive 
domains, nor did they amount to a diagnostic determination of dementia. Other measurements such as 
Clinical Dementia Rating (CDR) and composites of several cognitive tests should be considered in future 
research. In addition, although we adjusted for many possible confounding variables, residual confounders 
by unmeasured variables remain a possibility. Individuals consuming omega-3 supplements might be self-
selected healthier lifestyles than those who do not. Besides, our measures of dietary intake of omega-3 
PUFA was limited to only fish consumption, which may vary in n3-PUFA content depending on the types of 
fish and preparations, hence may not correlate well with the actual total amounts of omega-3 fatty acid 
intake. Deep sea fatty fish which are more abundant in omega-3 PUFA is less prevalent in the local 
population, and this may explain the lack of significant association obtained with the analysis of our data.  
More objective and accurate measures for assessing omega-3 PUFA intake should use serum or red blood 
cell membranes levels of n3-PUFA (236).  
 
In conclusion, the data in this observational study supports the suggestion that daily consumption of omega-
3 polyunsaturated fatty acid supplements may be beneficial in preventing cognitive decline in individuals 
without dementia. However, data from more prospective and interventional studies with larger sample size 
should provide firmer evidence to support the use of n-3 PUFA’s in slowing cognitive decline in elderly 






   
4.2 Study II 
4.2.1 Results 
The baseline characteristics of the 710 non-demented Chinese Singaporean participants are described in 
Table 3. The mean age of the study population was 64.5 (SD=6.7, range: 55-88), and a larger proportion 
were female (61.4%). 50.4% of the participants had 6 years of schooling or less. There were only small 
proportions of regular alcohol drinkers (2.1%) and smokers (ex-smokers and current smokers: 14.5%). 
Hypertension was present in more than one-half of the study population (53.4%), and diabetes in 13.4%, 
stroke in 2.0%. Altogether, 8.9% of the respondents had ischaemic heart disease, congestive heart failure, or 
atrial fibrillation. The frequency of APOE ε4 carrier was reported by 15.8%. The mean BMI of the study 
population was 23.7 (SD=3.5) and 33.1% had low level of leisure-time activities.  
 
Among the total 710 study participants, 49 (6.9%) of them reported daily consumption of n-3 PUFA 
supplements (6.9%), and the other 661 participants consumed omega-3 supplements less than daily (93.1%).  
 
Comparing n-3 PUFA supplements daily users and less-than-daily users, the daily users were found to be 
significantly with higher levels of education (P=0.010) and higher levels of leisure-time activities (P=0.010). 
There were no significant differences in age, gender, smoking status, alcohol drinking, hypertension, 
diabetes, stroke, heart disease, depressive symptoms, APOE ε4 status, vegetable and fruit intake, fish intake 
and coffee consumption.  
 
The whole participants’ cognitive performance is shown in Table 4. Among the total 710 subjects, the mean 
MMSE total score was 27.9 (SD=1.7). 558 participants completed both Digit Span and Spatial Span tests, 
with a summed Z score of attention domain 0.44 (SD=2.7). 558 participants completed both RAVLT and 
Visual Reproductive tests, with a summed Z score of memory domain -0.88 (SD=2.4). 478 participants 
completed both the categorical verbal fluency test and three conditions of Design Fluency tests, with a 
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summed Z score of executive function domain 0.35 (SD=3.1). 392 participants completed both the written 
and oral version of the Symbol Digits Modalities Test (SDMT), with a summed Z score of information 
processing speed domain 0.20 (SD=1.9).  
 
Compared with those who were omega-3 supplements less-than-daily users, participants who consumed 
omega-3 supplements daily showed significantly better performance on MMSE (P=0.021), verbal attention 
(P=0.033), memory (P=0.001), executive function (P=0.002), information processing speed (P=0.004) 
(Table 5). 
 
Table 6 shows the association between daily consumption of omega-3 supplements and cognitive 
performance. In the univariate logistic regression model (model 1), daily users of omega-3 supplements had 
significantly higher scores for MMSE and all the neurocognitive domains except the Attention score 
(P=0.12). After controlling for age, gender and education, the association remained significant except for 
MMSE (P=0.145). After further controlling for smoking, alcohol consumption, BMI, hypertension, diabetes, 
stroke, heart disease, depressive symptoms, level of leisure-time activities, APOE ε4 status, vegetable and 
fruit consumption, fish consumption and coffee consumption, daily intake of omega-3 supplements was 
significantly associated with better performance on Memory (SE=0.31, β=0.098, P=0.006), Executive 








   
          Table 3 Baseline descriptions of the study participants, for whole sample and by intake of omega-3 PUFA supplements  
 
 
Baseline characteristics Whole sample 
 Daily intake of omega-3 supplements   
P  
 Yes  No  
Sample size  710  49  661   
1
Age (y) 64.5 ± 6.7   63.1 ± 5.5   64.6 ± 6.8   0.20 
Female [n (%)] 436 (61.4)  35 (71.4)  401 (60.7)  0.14 
≤Primary education [n (%)] 358 (50.4)  16 (32.7)  342 (51.7)  0.010 
Ex-smoker or current smoker [n (%)] 103 (14.5)  7 (14.3)  96 (14.5)  0.96 




) 23.7 ± 3.5  24.3 ± 3.7  23.7 ± 3.5  0.27 
Hypertension [n (%)] 379 (53.4)  23 (46.9)  356 (53.9)  0.35 
Diabetes mellitus [n (%)] 95 (13.4)  3 (6.1)  92 (13.9)  0.12 
Heart disease [n (%)] 63 (8.9)  3 (6.1)  60 (9.1)  0.61 
History of stroke [n (%)] 14 (2.0)  1 (2.0)  13 (2.0)  1.00 
Depressive symptoms [n (%)] 104 (14.6)  11 (22.4)  93 (14.1)  0.11 
2
APOE ε4 carrier [n (%)] 112 (15.8)  7 (14.3)  105 (15.9)  0.77 
Low level of leisure-time activities [n (%)] 235 (33.1)  8 (16.3)  227 (34.3)  0.010 
Eat ≥1 serving vegetable and fruit/d [n (%)] 669 (94.2)  47 (95.9)  622 (94.1)  1.00 
Eat >3 servings fish/wk [n (%)] 645 (90.8)  47 (95.9)  598 (90.5)  0.30 
Consume coffee daily [n (%)] 450 (63.4)  29 (59.2)  421 (63.7)  0.53 
                  
                 1
 Mean ± SD; range in parentheses (all such values).  
           
2
APOE: apolipoprotein E. 
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 Table 4 Cognitive performance of the whole study participants 
 
Cognitive tests  n Min Max Mean SD 
Global cognitive functioning      
  MMSE total score 710 24 30 27.9 1.7 
Attention      
  Digit span forward longest span 664 4 11 6.8 1.5 
  Digit span backward longest span 656 0 9 4.2 1.3 
  Spatial span forward longest span 565 0 10 4.8 1.1 
  Spatial span backward longest span 563 0 8 4.4 1.3 
  ZTotal verbal attention 656 -3.6 6.0 0.18 1.7 
  ZTotal spatial attention 563 -5.3 4.8 0.23 1.6 
  Attention score 558 -6.6 9.3 0.44 2.7 
Memory      
  
1
RAVLT immediate recall 612 5 73 44.3 9.9 
  
1
RAVLT delayed recall 587 0 15 9.2 3.2 
  Visual Reproduction immediate recall 592 11 102 66.6 17.8 
  Visual Reproduction delayed recall 577 0 100 41.1 20.7 
  ZTotal verbal memory 587 -4.5 1.7 -1.2 1.0 
  ZTotal spatial memory 576 -4.2 4.7 0.28 1.7 
  Memory score 558 -7.9 4.8 -0.88 2.3 
Executive function      
  Categorical verbal fluency 583 16 82 42.3 9.2 
  Design fluency condition 1  497 0 18 7.1 3.2 
  Design fluency condition 2 496 0 19 7.8 3.4 
  Design fluency condition 3 496 0 15 5.2 2.8 
  Executive Function score 478 -6.2 10.9 0.35 3.1 
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Information Processing Speed      
  Symbol Digits Modalities Test        
    Written version 393 4 66 34.7 13.2 
    Oral version  392 7 74 42.5 14.1 
 Information Processing Speed score 392 -4.2 4.5 0.20 1.9 
 
1
RAVLT: Rey Auditory Verbal Learning Test.
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  Table 5 Cognitive performance of the study participants by intake of omega-3 PUFA supplements 
 
Cognitive tests 
 daily users of omega-3 PUFA supplements  
P Yes  No  
n Min Max Mean SD  n Min Max Mean SD  
Global cognitive functioning              
  MMSE total score 49 24 30 28.5 1.5  661 24 30 27.9 1.8  0.021 
Attention              
  Digit span forward longest span 46 5 10 6.9 1.5  618 4 11 6.8 1.5  0.76 
  Digit span backward longest span 46 3 8 4.7 1.2  610 0 9 4.2 1.3  0.003 
  Spatial span forward longest span 40 3 7 4.8 0.91  525 0 10 4.8 1.1  0.56 
  Spatial span backward longest span 40 0 7 4.5 1.2  523 0 8 4.4 1.3  0.20 
  ZTotal verbal attention 46 -2.0 5.2 0.63 1.6  610 -3.6 6.0 0.15 1.7  0.033 
  ZTotal spatial attention 40 -3.6 4.0 0.36 1.3  523 -5.33 4.77 0.22 1.6  0.66 
  Attention score 40 -4.8 8.5 1.1 2.7  518 -6.6 9.3 0.39 2.7  0.094 
Memory              
  
1
RAVLT immediate recall 45 27 59 49.4 7.3  567 5 73 43.8 10.0  0.000 
  
1
RAVLT delayed recall 45 3 15 10.4 2.7  542 0 15 9.14 3.3  0.019 
  
2
VR immediate recall 44 18 101 73.4 17.8  548 11 102 66.1 17.7  0.002 
  
2
VR delayed recall 43 0 93 47.4 20.5  534 0 100 40.6 20.7  0.030 
  ZTotal verbal memory 45 -3.1 0.41 -0.69 0.78  542 -4.5 1.7 -1.2 1.0  0.000 
  ZTotal spatial memory 43 -3.5 4.4 0.97 1.6  533 -4.2 4.7 0.22 1.7  0.006 
  Memory score 43 -5.7 4.8 0.29 2.1  515 -7.9 4.7 -0.98 2.3  0.001 
Executive function              
  Categorical verbal fluency 47 26 76 45.1 10.0  536 16 82 42.1 9.1  0.053 
  Design fluency condition 1  40 3 17 8.25 3.3  457 0 18 7.0 3.2  0.023 
  Design fluency condition 2 40 4 16 9.1 2.9  456 0 19 7.7 3.5  0.006 
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  Design fluency condition 3 40 0 12 5.8 2.6  456 0 15 5.2 2.8  0.12 
  Executive Function score 40 -5.6 7.8 1.6 2.7  438 -6.2 10.9 0.23 3.1  0.002 
Information Processing Speed              
  Symbol Digits Modalities Test - Written 32 16 55 40.9 11.0  361 4 66 34.1 13.2  0.003 
  Symbol Digits Modalities Test – Oral 32 27 69 49.1 11.4  360 7 74 41.9 14.2  0.006 
  Information Processing Speed score 32 -2.2 3.2 1.1 1.5  360 -4.2 4.5 0.12 1.9  0.004 
 
1
RAVLT: Rey Auditory Verbal Learning Test. 
 
2

















   
 




         Model 1  Model 2          Model 3  
SE β P   SE β P  SE β P 
Global cognitive functioning             
  MMSE total score 0.26 0.088 0.019  0.23 0.050 0.15  0.23 0.042 0.22 
Attention           
  Digit span forward longest span 0.23 0.013 0.75  0.22 0.001 0.97  0.23 -0.002 0.95 
  Digit span backward longest span 0.20 0.11 0.004  0.18 0.081 0.023  0.18 0.081 0.025 
  Spatial span forward longest span 0.19 0.002 0.96  0.17 -0.020 0.62  0.18 -0.022 0.59 
  Spatial span backward longest span 0.21 0.034 0.42  0.20 0.015 0.69  0.20 0.007 0.87 
  ZTotal verbal attention 0.26 0.074 0.059  0.24 0.049 0.18  0.24 0.046 0.21 
  ZTotal spatial attention 0.26 0.022 0.61  0.24 -0.003 0.95  0.24 -0.009 0.81 
  Attention score 0.44 0.067 0.12  0.39 0.037 0.32  0.39 0.033 0.38 
Memory            
  
1
RAVLT immediate recall 1.5 0.15 0.000  1.39 0.10 0.005  1.4 0.11 0.003 
  
1
RAVLT delayed recall 0.50 0.10 0.013  0.48 0.067 0.088  0.48 0.074 0.066 
  
2
VR immediate recall 2.77 0.11 0.009  2.4 0.070 0.044  2.4 0.068 0.054 
  
2
VR delayed recall 3.3 0.087 0.037  2.9 0.045 0.22  3.0 0.052 0.16 
  ZTotal verbal memory 0.16 0.14 0.001  0.14 0.10 0.009  0.14 0.11 0.004 
  ZTotal spatial memory 0.27 0.12 0.006  0.23 0.070 0.048  0.23 0.07 0.04 
  Memory score 0.37 0.14 0.001  0.31 0.091 0.010  0.31 0.098 0.006 
Executive function            
  Categorical Verbal Fluency 1.4 0.091 0.028  1.3 0.048 0.20  1.3 0.040 0.30 
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  Design Fluency condition 1 0.53 0.10 0.023  0.47 0.069 0.079  0.48 0.062 0.12 
  Design Fluency condition 2 0.57 0.11 0.023  0.50 0.074 0.061  0.50 0.073 0.068 
  Design Fluency condition 3 0.46 0.063 0.16  0.41 0.03 0.43  0.42 0.029 0.47 
  Executive Function score 0.51 0.12 0.007  0.45 0.078 0.030  0.43 0.071 0.046 
Information Processing Speed            
3
SDMT written  version 2.4 0.14 0.005  1.7 0.080 0.024  1.7 0.073 0.037 
3
SDMT oral version 2.6 0.14 0.006  1.9 0.081 0.030  1.9 0.072 0.051 
Information  Processing Speed score 0.34 0.14 0.005  0.24 0.082 0.022  0.24 0.074 0.036 
 
   1
RAVLT: Rey Auditory Verbal Learning Test. 
   2
VR: Visual Reproduction. 
   3










   
4.2.2 Discussion 
In this community-based study of older Chinese Singaporeans aged 55 and above, we found that daily intake 
of omega-3 PUFA supplements were significantly associated with better cognitive performance on cognitive 
domains of Memory, Executive Function and Information Processing Speed.  
 
Long chain omega-3 polyunsaturated fatty acids (omega-3 PUFAs), primarily eicosapentaenoic acid (EPA, 
C20:5n-3) and docosahexaenoic acid (DHA, C22:6n-3), have been extensively studied for their potential 
benefits in slowing cognitive decline in non-demented individuals or reducing the risks or progression of 
dementia in Alzheimer’s disease. To date, four cross-sectional studies have used neurocognitive test battery 
to examine the relationship between plasma level of n-3 PUFA, or dietary n-3 PUFA (seafood or fish 
consumption) and cognitive function in the elderly. In a substudy of the Hordland Health Study (HUSK), a 
cognitive test battery including six tests was performed among 2031 subjects in Western Norway: Kendrick 
Object Learning Test, Trail Making Test (part A), modified versions of the Digit Symbol Test, Block 
Design,  Mini-Mental  State Examination, and Controlled Oral Word Association Test. The findings showed 
that individuals with a diet high in seafood (fish and fish products) had a better cognitive test performance 
on all the cognitive tests compared to those with lower intake of fish and fish products (81). Similar results 
were found by Kalmijn S et al in 2004. In this study, cognitive performance was assessed by an extensive 
cognitive battery that included memory, psychomotor speed, cognitive flexibility and overall cognitive 
function. Consumptions of both marine omega-3 PUFA (EPA and DHA) and fatty fish were inversely 
associated with the risk of impaired overall cognitive function and speed (79). In addition, one nested case-
control study examined the cognitive performance between fish-oil users and food supplement nonusers. 
The assessment of cognitive performance was covered by a full range of cognitive tests including Raven’s 
Standard Progressive Matrices, the Rey Auditory Verbal Learning Test, the uses of common objects test, 
and the digit symbol subtest of the Wechsler Adult Intelligence Scale-revised and the block design subtest of 
the Wechsler Adult Intelligence Scale-revised. The findings showed that, at the age of 64y, compared with 
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fish-oil nonusers, fish-oil users had significantly higher block design scores before adjustments for 
childhood IQ (84). However, In the cross-sectional analysis from 1025 elderly men recruited in the Veterans 
Affairs Normative Aging Study, neither fatty fish intake nor n-3 PUFA was found to be associated with 
cognitive performance that measured by memory/language, speed, and visuo-spatial/attention. Similarly, in 
another cross-sectional analysis from Netherlands which included 807 men and women aged 50-70y,  
plasma n-3 PUFA proportions was not associated with any of the performance of five tested cognitive 
domains (memory, sensorimotor speed, complex speed, information-processing speed and word fluency) 
(109). 
 
This study provides preliminary findings in the relationship between omega-3 supplements daily 
consumption and cognitive functioning among elderly in Asian population, by using a full battery of 
comprehensive neurocognitive tests that assessed a wide range of cognitive domains. The test battery for 
analysis included an extensive series of seven neurocognitive assessments, including Digit Span, Spatial 
Span, Rey Auditory Verbal Learning Test (RAVLT), Visual Reproduction (VR), Categorical Verbal 
Fluency tests, written and oral version of Symbol Digit Modalities Test (SDMT). The Digit Span test 
assesses verbal attention, whereas the Spatial Span test assesses spatial attention. Similarly, the RVALT 
measures the verbal memory and the VR measures the spatial memory. Both Categorical Verbal Fluency 
tests and Design Fluency tests are designed to assess executive function. SDMT tests assess the speed for 
information processing. In the current study, after adjustment for potential confounders (age, gender, 
education, smoking, alcohol consumption, BMI, hypertension, diabetes, stroke, heart disease, depressive 
symptoms, level of leisure-time activities, APOE ε4 status, vegetable and fruit consumption, fish 
consumption and coffee consumption), omega-3 supplements daily consumers were found to have better 
performance on the cognitive domains of Memory (SE=0.31, β=0.098, P=0.006), Executive Function 
(SE=0.43, β=0.071, P=0.046) and Information Processing Speed (SE=0.24, β=0.074, P=0.036). However, 
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the association between omega-3 supplements intake and the Attention domain was not statistically 
significant (SE=0.39, β=0.033, P=0.37).  
 
In addition, the Mini-Mental State Examination (MMSE) test was administered in the present study to assess 
global cognitive functioning among the community-dwelling elderly. We compared the baseline MMSE 
score between omega-3 supplements daily users and less-than-daily users, and found that those consumed 
omega-3 supplements daily had significantly higher MMSE scores than those consumed omega-3 less-than-
daily (28.5 and 27.9 respectively, P=0.021), indicating that omega-3 supplements intake could be beneficial 
on MMSE performance. However, after controlling for multiple confounders (e.g. age, gender and 
education), we failed to find a significant independent association between omega-3 supplements intake and 
baseline MMSE scoring (SE=0.23, β=0.042, P=0.22). A previous local study found that the MMSE test 
performance was much better in higher educated subjects in Asia, with a higher specificity of 85.2%) (222). 
In our study, comparing with those omega-3 supplements less-than-daily consumers, the daily users were 
less likely to have poor education (6 years or less) (32.7% and 51.7%, P=0.010). Therefore, after adjusting 
for potential confounders such as education, the effect of omega-3 supplements on MMSE performance was 
less significant. 
 
The neuroprotective effect of n-3 PUFAs is well supported by biological evidence from experimental studies.  
It has been suggested that both EPA and DHA could reduce cardiovascular risk factors and improve cerebral 
blood flow, reduce inflammation, and directly limit Alzheimer disease (AD) pathology. Long chain n-3 
PUFAs play key roles in brain development, synaptic plasticity and neurotransmission. They provide 
protection against cardiovascular events by lowering blood triacylglycerols, improving platelet aggregation 
and endothelial function, and being antiarrhythmia. Furthermore, the n-3 PUFAs attenuate inflammation by 
inhibiting the synthesis of proinflammatory cytokines. Given that high levels of inflammation, possibly due 
to β-amyloid peptides, could contribute to cognitive decline, omega-3 fatty acids could have neuroprotective 
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effects through their anti-inflammatory properties. Omega-3 fatty acids have been found to increase the 
density of dendritic spines (66-67) and synaptic proteins (66-68), enhance hippocampal neurogenesis (69),  
increase cerebral blood volume (70-71), decrease cholesterol in membranes (72-73), reduce AA and its 
metabolites (59,74), reduce the amyloid-β (Aβ) burden, reduce Aβ40 and Aβ42 levels in the hippocampus (75), 
reduce tau levels, and reduce phosphorylation and conformational changes in tau (74). However, the 
mechanism of the neuroprotective effects of n-3 PUFAs on specific brain areas tapped by the different 
cognitive tests is still unclear. 
 
The strength of our study included the use of a standardized comprehensive battery of seven 
neuropsychological tests to assess different cognitive domains. Besides, we adjusted for many possible 
confounding variables, e.g. age, gender, education, smoking, alcohol consumption, BMI, hypertension, 
diabetes, stroke, heart disease, depressive symptoms, level of leisure-time activities, APOE ε4 status, 
vegetable and fruit consumption, fish consumption and coffee consumption.  
 
However, there are some limitations. First, the cross-sectional study design does not provide any 
information on causal effect of omega-3 supplements intake on cognitive performance. Due to the small 
numbers of SLAS-1 participants who completed both baseline and follow-up neuropsychological tests 
(n=320), there might be not sufficient statistical power for a longitudinal cohort analysis. Second, the 
analysis was based on a relative small number of omega-3 supplements daily users (n=49). Although the 
sample size could be large enough to produce a sufficient statistical power, the results should be interpreted 
cautiously. Further studies with more participants could reach an adequate power to provide firmer evidence. 
Third, not all subjects completed the whole neuropsychological test battery because of participant 
compliance. As tests vary in difficulty and without the same subjects performing all of the same tests, each 
neuropsychological test should be considered as separate findings rather than as a global indicator of 
cognitive performance. Fourth, although we adjusted for multiple potential confounders, residual 
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confounding factors by unmeasured variables remain a possibility. Individuals consuming omega-3 
supplements might be self-selected healthier lifestyles than those who do not. Finally, the consumption 
omega-3 supplements was measured by only asking “For the past 12 months, do you regularly consume 
omega-3 supplements?”. Information such as dosage and duration of omega-3 supplements consumption 
would also be collected. More objective and accurate measures for assessing omega-3 PUFA intake should 
use serum or red blood cell membranes levels of n3-PUFA. 
 
In conclusion, our findings suggest that daily consumption of omega-3 supplements could be possibly 
preventative for cognitive decline and dementia. This should be more clearly established in future 
longitudinal study with larger sample size and information on dosage and duration of omega-3 supplements 
















   
4.3 Study III 
4.3.1 Results 
Of the 306 participants, 182 (59.5%) were women; mean age was 74.3 (range=55-89). There were no 
significant differences between demented patients and controls in term of age (P=0.814) and sex (P=1.000). 
By contrast, more patients had less than 6 years of education compared to control subjects (88.2% and 
59.5% respectively, P<0.001). 
 
Altogether, 52 of 153 dementia patients were APOE ε4 carriers (34.0%). No significant difference of APOE 
ε4 prevalence was observed between AD and non-AD (VaD and mixed dementia) group (35.6% and 31.8%, 
P=0.622) (Table 7). 
 
Between all dementia patients and matched controls, the prevalence of APOE ε4 carriers among patients 
was significantly higher than in controls (34.0% and 19.0% respectively, P=0.003) (Table 8a). Furthermore, 
we found a significant association of APOE ε4 carriers with the risk of developing dementia after controlling 
for education (OR=2.568, 95% CI 1.350-4.883, P=0.004) (Table 8b). 
 
Between AD patients and healthy controls, compared to control subjects, the prevalence of APOE ε4 carriers 
was significantly higher among AD patients (35.6% and 17.2%, P=0.005) (Table 9a). Moreover, the 
unadjusted OR of the association of APOE ε4 carriers with AD was 2.41, 95% CI 1.10-5.28, P=0.028 
(adjusted for education Table 9b).  
 
Finally, among the non-AD (VaD/mixed dementia) patients and age- and sex- matched controls, there was 
no significantly difference of APOE ε4 prevalence between the two groups (31.8% and 21.2%, P=0.168) 
(Table 10a). No significant association of APOE ε4 allele with non-AD dementia was found (adjusted 
OR=1.69, 95% CI 0.66-4.33, P=0.28) (Table 10b).
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Table 7 APOE ε4 allele status in dementia patients (n=153) 
 




















101 (66.0) 56 (64.4) 45 (68.2) 
 
 
     P value for χ2 test of differences in APOE ε4 status between AD and non-AD (VaD and mixed dementia) patients. 
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       Table 8a APOE ε4 allele distribution in dementia cases and controls  
 
  














P value: for χ2 test of differences in APOE ε4 allele frequencies between demented patients and age- and sex-matched controls. 
 
       Table 8b Association of APOE ε4 allele and dementia 
 
Model 1  Model 2 













       Model 1: Unadjusted.  Model 2: Adjusted for education. 
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       Table 9a APOE ε4 allele distribution in AD cases and controls  
 
  














P value: for χ2 test of differences in APOE ε4 allele frequencies between AD patients and age- and sex-matched controls. 
 
       Table 9b Association of APOE ε4 allele and AD 
 
Model 1  Model 2 












       Model 1: Unadjusted.  Model 2: Adjusted for education. 
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       Table 10a APOE ε4 allele distribution in non-AD cases and controls  
 
  














P value: for χ2 test of differences in APOE ε4 allele frequencies between non-AD patients and age- and sex-matched controls. 
 
       Table 10b Association of APOE ε4 allele and non-AD 
 
Model 1  Model 2 













       Model 1: Unadjusted.  Model 2: Adjusted for education.
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4.3.2 Discussion 
This case-control study examined the association between APOE ε4 allele and the risk of developing 
dementia (both AD and non-AD dementia) in a Singaporean Chinese population. We found that the 
prevalence of APOE ε4 allele was significantly higher among AD patients than controls. Moreover, APOE 
ε4 allele carriers had a higher risk of developing AD, but not non-AD, than non-carriers. This positive 
association remained unchanged after controlling for potential confounders.  
 
APOE ε4 has been the only consistently confirmed genetic risk factor for late-onset AD, which is the most 
common subtype of dementia in the general population. In 1993, Strittmatter and Saunders et al. first 
reported that the APOE ε4 allele frequency was significantly higher in patients with late-onset familial 
Alzheimer disease than in age-matched unrelated controls (0.5 +/- 0.06 and 0.16 +/- 0.03 respectively, 
P=0.014) (173). They also found that compared to homozygous ε3/ ε3 carriers, the odds ratios of developing 
AD was 3.2 (95% CI 2.9-3.5) and 11.6 (95% CI 8.9-15.4) for carriers of one or two APOE ε4 alleles, 
respectively (172). So far, the underlying mechanism of the effect of APOE ε4 on the pathogenesis in AD 
remains unclear, although current evidence suggests that it could promote Aβ peptide deposition and 
decrease its clearance, causing AD. 
 
As has been observed across global populations, the APOE ε4 allele carrier prevalence in patients diagnosed 
with AD varied by geographic location. Patients recruited in Northern Europe seemed to have significantly 
highest APOE ε4 carrier status estimates (61.3%, 95 % CI 55.9-66.7) than those recruited in Asia (41.9%, 
95% CI 38.5-45.3) or Southern Europe/Mediterranean (40.5%, 95% CI 36.8-44.1) (180). This trend is 
consistent with the published general population studies in which the APOE ε4 were observed to be more 
common in Northern Europe than in Southern Europe and Asia, and to be lowest in Sardinians (5.2%), 
Greeks (6.8%) and Chinese (7.1%) (248). In the present study, the prevalence of APOE ε4 allele was 35.6% 
in AD patients and 31.8% in non-AD demented patients, which is similar with the previous results from 
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another observational study in Singapore (182). Moreover, we also found that the prevalence of APOE ε4 
allele was significantly different between AD patients and age- and sex-matched controls (35.6% and 17.2%, 
P=0.005), but this difference was not observed among non-AD patients and controls. 
 
On the other hand, the association between APOE ε4 carrier status and the risk of AD has been replicated 
and confirmed in numerous studies conducted worldwide, although the strength of the association is 
inconsistent among different ethnic and geographic groups. Compared with ε3/ε3 genotype carriers, the 
relative risk (RR) of AD associated with the presence of at least one ε4 allele was significantly increased 
among whites (RR 2.5, 95% CI 1.1-6.4), but not among African Americans (RR 1.0, 95% CI 0.6-1.6) or 
Hispanics (RR 1.1, 95% CI 0.7-1.6) (249). In this study, the odds ratio of the association between carriers of 
at least one APOE ε4 allele and the risk of AD was 2.41 after controlling for education (95% CI 1.10-5.28, 
P=0.028), indicating that the presence of APOE ε4 allele is associated with increased risk of AD and appears 
to be an independent risk factor of developing AD in Singaporean Chinese population. However, such 
relationship was not found among non-AD demented patients in the present study. 
 
In Singapore, compared with AD, VaD is more common among demented patients aged 50 to 69 (19). 
Although APOE ε4 allele is a well-established susceptibility gene for AD, its relationship with VaD is still 
controversial. As summarized by Liu et al. in 2011, the association between APOE gene polymorphism and 
VaD has been observed in the population in USA, UK, Hungary and Netherlands, but not in the population 
of Korea, Belgium, Japan and Finland (190). In this study, we also failed to find a significant relationship 
between APOE ε4 allele and the risk of developing non-AD (VaD and mixed dementia) in a Singaporean 
Chinese population. From previous research findings, APOE ε4 allele has been linked to higher risk of 
atherosclerosis, coronary artery disease, ischemic stroke and hypertension. All these cardiovascular risk 
factors and diseases are identified risk factors of VaD (250). This suggests that APOE ε4 could play a role in 
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the development of VaD by acting on these risk factors. Further studies are required to establish a more 
reliable risk assessment for VaD in Singapore.  
 
The study has limitations. First, the sample size is not large enough, with 153 all-cause dementia patients (87 
AD and 66 non-AD) and 153 age- and sex- matched controls. Further studies with more participants could 
reach an adequate power to provide firmer evidence. Second, as a case-control study design, survival bias 
and hospital selection (Bergson’s) bias cannot be excluded from the demented patients in this study. 
Therefore, the APOE ε4 allele frequency among these demented patients may not be generalized to the 
prevalence of APOE ε4 allele in patients with dementia nationwide in Singapore. Third, this study only 
included Chinese subjects and the ethnic variability in dementias should also be considered. In Singapore, 
Ampil et al. reported that VaD was more common among Chinese and Malays, whereas AD was more 
common in Indians and Eurasians (181).  In addition, Sahadevan et al. found that Malays had twice the risk 
for AD and Indians had more than twice the risk for AD and VaD, compared with Chinese population (19). 
APOE ε4 allele distribution and its association with dementia could be different due to various ethnic groups. 
Further case-control studies with Malays and Indians are necessarily recommended. Finally, as APOE ε4 
cannot contribute to all AD cases, other genetic factors have also been reported for their interaction with AD 
development (251). Further studies are required to examine the gene-gene interaction. 
 
In conclusion, this case-control study suggests that although associated with AD among Singaporean 
Chinese, the effect of APOE ε4 in increasing the risk of AD was not strong as that observed in Western 
populations. No significant association was observed with non-AD dementia. More studies using larger 





   
4.4 Study IV 
4.4.1 Results 
The study included 109 AD patients and 77 mixed dementia patients (mean age 77.3 years, 67.7% women). 
More than half had hypertension (65.1%) and 47.3% had hyperlipidemia (Table 11).  
 
The distribution of PON1 192 Q/R genotypes and allele frequencies in the study population is presented in 
Table 12. The genotypes were in Hardy-Weinberg equilibrium and their distribution was not significantly 
different between AD patients and mixed dementia patients (9 QQ, 54 QR, 46 RR; 9 QQ, 39 QR, 29 R/R 
respectively, P=0.673). In addition, the presence of at least one R allele (Q/R or R/R) and the presence of at 
least one Q allele (QR or QQ) were not significantly different between AD patients and mixed dementia 
patients (91.7% and 88.3%, P=0.436; 57.8% and 62.3%, P=0.534 respectively). Likewise, allele distribution 
was not significantly different between the two groups: the Q allele frequency was 33.0% in AD patients and 
37.9% in mixed dementia patients, while the R allele frequency was 67.0% in patients with AD and 63.1% 
in patients with mixed dementia (P=0.426). The ratio between Q and R allele frequency was 0.493 in AD 
patients and 0.588 in mixed dementia patients. 
 
In the whole patient population, R allele carriers, compared with non R allele carriers, showed higher mean 
NPI-Q (S) scores and NPI-Q (CD) scores (8.80 versus 4.89, P=0.004; 8.92 versus 3.94, P=0.002 
respectively). There were no significantly differences in MMSE score (P=0.426), GCDR score (P=0.928), 
total CDR score (P=0.407), GDS/FAST score (P=0.283), and BADL score (P=0.303) (Table 14a). 
 
In the mixed dementia group, the presence of R allele was significantly associated with pronouncedly higher 
mean NPI-Q (S) scores (9.01 versus 3.11, P=0.039) and NPI-Q (CD) scores (9.09 versus 2.33, P=0.006), as 
well as with CDR (Total) score (8.57 versus 5.89, P=0.042), GDS/FAST score (4.84 versus 4.11, P=0.007) 
and BADL score (6.99 versus 1.00, P<0.001). In contrast, among patients in the AD subgroup, no 
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significant differences in any of these measurements between R allele carriers and non-carriers were found 
(Table 14a).  
 
Furthermore, we analyzed the prevalence of various neuropsychiatric symptoms of the 186 demented 
patients by PON1 192Q/R polymorphism and among dementia subgroups. In the whole population, the 
prevalence of delusion was significantly higher among patients with QR genotype than those with QQ 
genotype (47.3% and 22.2% respectively, P=0.050) (Table 13b). In the mixed dementia subgroup, R allele 
carriers, compared with non R allele carriers, showed significantly lower prevalence of elation/euphoria 
(11.9% versus 100.0%, P<0.001) and higher prevalence of nighttime behaviors (49.3% vs 11.1%, P=0.037) 
(Table 14b).  
 
Table 11 Demographic characteristics of the study population (n=186)  
 Overall 
Age, years, mean (SD) 77.3 (7.1) 
Female gender, n (%) 126 (67.7) 
AD, n (%)  109 (58.6) 
Mixed dementia, n (%) 77 (41.4) 
Diabetes, n (%) 52 (28.0) 
Hypertension, n (%) 121 (65.1) 
Hyperlipidemia, n (%) 88 (47.3) 
Stroke, n (%) 20 (10.8) 
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       Table 12 PON1 192 Q/R genotype distributions and allele frequencies in the study population 
Group No. 
Genotype, n (%) 
P1 P2 P3 
Allele, n (%) 
P4 
QQ QR RR Q R Q/R  
AD 109 9 (8.3) 54 (49.5) 46 (42.2) 
0.673 0.436 0.534 
72 (33.0) 146 (67.0) 0.493 
0.426 
Mixed Dementia 77 9 (11.7) 39 (50.6) 29 (37.7) 57 (37.9) 97 (63.1) 0.588 
Total 186 18 (9.7) 93 (50.0) 75 (40.3)    129 (34.7) 243 (65.3) 0.531  
 
                  P1 value for χ2 test of differences in PON1 genotype frequencies between AD and mixed dementia patients.  
                  P2 value for χ2 test of differences in (QR + RR) and QQ genotype between AD and mixed dementia patients.  
                  P3 value for χ2 test of    differences in (QR + QQ) and RR genotype between AD and mixed dementia patients.  
                  P4 value for χ2 test of differences in PON1 allele frequencies between AD and mixed dementia patients.  
                  PON1: paraoxonase 1.  
                  AD: Alzheimer’s disease. 
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 P values (from 2 test) 
 RR vs QR RR vs QQ QR vs QQ 
MMSE score (mean/SD) 15.8 (6.30) 15.6 (5.81) 16.9 (5.06)  0.829 0.508 0.390 
Global CDR score (mean/SD) 1.52 (0.67) 1.41 (0.59) 1.47 (0.56)  0.254 0.780 0.673 
CDR (total) score (mean/SD) 8.47 (3.86) 8.07 (3.49) 7.50 (3.15)  0.480 0.327 0.526 
GDS/FAST score (mean/SD) 4.71 (0.90) 4.74 (0.85) 4.50 (0.62)  0.794 0.358 0.251 
NPI-Q (S) score (mean/SD) 8.85 (8.20) 8.76 (8.42) 4.89 (4.51)  0.945 0.008 0.007 
NPI-Q (CD) score (mean/SD) 8.65 (9.89) 9.13 (9.36) 3.94 (5.22)  0.750 0.007 0.002 
Bristol ADL score (mean/SD) 7.29 (10.2) 6.24 (7.56) 4.50 (6.70)  0.455 0.271 0.366 
 
 MMSE = mini mental state examination. CDR = clinical dementia rating.  NPI-Q = neuropsychiatric inventory questionnaire. 
 BADL = Bristol activities of daily living.  GDS/FAST = global deterioration scale/functional assessment staging system.  
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 P values (from 2 test) 
 RR vs QR RR vs QQ QR vs QQ 
Delusions, n (%) 26 (35.1) 43 (47.3) 4 (22.2)  0.117 0.295 0.050 
Hallucinations, n (%) 15 (20.3) 22 (24.2) 3 (16.7)  0.550 1.000 0.759 
Agitation/Aggression, n (%) 36 (48.6) 50 (54.9) 9 (50.0)  0.421 0.918 0.700 
Depression/Dysphoria, n (%) 35 (47.3) 37 (40.7) 6 (33.3)  0.393 0.285 0.561 
Anxiety, n (%) 29 (39.2) 40 (44.0) 5 (27.8)  0.537 0.368 0.203 
Elation/Euphoria, n (%) 9 (12.2) 8 (8.8) 2 (11.1)  0.479 1.000 0.669 
Apathy/Indifference, n (%) 39 (52.7) 51 (56.0) 9 (50.0)  0.668 0.837 0.638 
Disinhibition, n (%) 30 (40.5) 31 (34.1) 5 (27.8)  0.392 0.317 0.604 
Irritability/Liability, n (%) 34 (45.9) 40 (44.0) 7 (38.9)  0.798 0.589 0.692 
Aberrant Motor Behavior, n (%) 22 (29.7) 32 (35.2) 7 (38.9)  0.459 0.453 0.763 
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Nighttime behaviors, n (%) 38 (51.4) 41 (45.1) 6 (33.3)  0.421 0.170 0.359 
Appetite/Eating Change, n (%) 23 (31.1) 36 (39.6) 4 (22.2)  0.258 0.459 0.163 
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Table 14a Clinical manifestations and severity of patients with dementia by PON1 192 Q/R allele status and among dementia subtypes 
 Whole sample  AD  Mixed dementia 













MMSE score (mean/SD) 15.7 (6.01) 16.9 (5.06) 0.426  15.7 (5.77) 14.7 (3.57) 0.596  15.7 (6.39) 19.1 (5.53) 0.134 
Global CDR score (mean/SD) 1.46 (0.63) 1.47 (0.56) 0.928  1.42 (0.595) 1.78 (0.441) 0.043  1.52 (0.672) 1.17 (0.500) 0.079 
CDR (total) score (mean/SD) 8.24 (3.66) 7.50 (3.15) 0.407  8.03 (3.36) 9.11 (2.26) 0.214  8.57 (4.06) 5.89 (3.19) 0.042 
GDS/FAST score (mean/SD) 4.73 (0.87) 4.50 (0.62) 0.283  4.65 (0.809) 4.89 (0.333) 0.099  4.84 (0.940) 4.11 (0.601) 0.007 
NPI-Q (S) score (mean/SD) 8.80 (8.30) 4.89 (4.51) 0.004  8.66 (8.39) 6.67 (3.78) 0.206  9.01 (8.23) 3.11 (4.68) 0.039 
NPI-Q (CD) score (mean/SD) 8.92 (9.58) 3.94 (5.22) 0.002  8.80 (9.69) 5.56 (4.90) 0.109  9.09 (9.47) 2.33 (5.29) 0.006 
Bristol ADL score (mean/SD) 6.71 (8.80) 4.50 (6.70) 0.303  6.52 (8.06) 8.00 (7.98) 0.598  6.99 (9.85) 1.00 (2.00) <0.001 
 
MMSE = mini mental state examination. CDR = clinical dementia rating.  NPI-Q = neuropsychiatric inventory questionnaire. 
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Table 14b Prevalence of neuropsychiatric symptoms of patients with dementia by PON1 192 Q/R allele status and among dementia subtypes 
 Whole sample  AD  Mixed dementia 













Delusions, n (%) 69 (41.8) 4 (22.2) 0.107  41 (41.8) 2 (22.2) 0.309  28 (41.8) 2 (22.2) 0.469 
Hallucinations, n (%) 37 (22.4) 3 (16.7) 0.767  23 (23.5) 1 (11.1)  0.680  14 (20.9) 2 (22.2) 1.000 
Agitation/Aggression, n (%) 86 (52.1) 9 (50.0) 0.864  50 (51.0) 5 (55.6) 1.000  36 (53.7) 4 (44.4) 0.728 
Depression/Dysphoria, n (%) 72 (43.6) 6 (33.3) 0.401  42 (42.9) 2 (22.2) 0.302  30 (44.8) 4 (44.4) 1.000 
Anxiety, n (%) 69 (41.8) 5 (27.8) 0.249  44 (44.9) 1 (11.1) 0.076  25 (37.3) 4 (44.4) 0.725 
Elation/Euphoria, n (%) 17 (10.3) 2 (11.1) 1.000  9 (9.2) 2 (22.2) 0.232  8 (11.9) 9 (100) <0.001 
Apathy/Indifference, n (%) 90 (54.5) 9 (50.0) 0.713  53 (54.1) 6 (66.7) 0.728  37 (55.2) 3 (33.3) 0.294 
Disinhibition, n (%) 61 (37.0) 5 (27.8) 0.441  39 (39.8) 3 (33.3) 1.000  22 (32.8) 2 (22.2) 0.711 
Irritability/Liability, n (%) 74 (44.8) 7 (38.9) 0.629  41 (41.8) 3 (33.3) 0.734  33 (49.3) 4 (44.4) 1.000 
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Aberrant Motor Behavior, n (%) 54 (32.7) 7 (38.9) 0.598  33 (33.7) 5 (55.6)  0.275  21 (31.3) 2 (22.2) 0.715 
Nighttime behaviors, n (%) 79 (47.9) 6  (33.3) 0.240  46 (46.9) 54 (55.6) 0.734  33 (49.3) 1 (11.1) 0.037 
Appetite/Eating Change, n (%) 59 (35.8) 4 (22.2) 0.251  38 (38.8) 3 (33.3) 1.000  21 (31.3) 1(11.1) 0.271 
 
            










   
4.4.2 Discussion 
This study provides distinct data on the distribution of PON1 gene 192Q/R polymorphism among elderly 
Chinese patients with AD and mixed dementia in Singapore. We found that 67% of AD patients and 63.1% 
of patients with mixed dementia carried at least one R allele. In contrast to populations of European descent 
where the Q allele is predominant, R allele is more frequent among Chinese patients with dementia in 
Singapore. This finding is similar to a previous study (52) conducted in China on a Chinese Han ethnic 
population, which reported that the PON1 R allele frequencies in AD patients were 0.61 (and 0.65 in healthy 
controls). Our study thus confirms the predominance of R allele amongst the Chinese with concordant 
findings among patients with dementia in both China and Singapore. The Chinese in Singapore are 
descendents of immigrants who migrated in the early 19
th
 century from the Southern provinces of China and 
were of Han ancestry. Altogether, these findings also highlights the substantial ethnic variations in the 
distribution of R and Q alleles in diverse populations in the world reported from previous studies (256-258).  
 
Little is known about the clinical effects of the presence of PON1 polymorphism among patients with 
dementia. Low serum levels of PON1 activity were reported in one study of AD patients compared to VaD 
(251).  While Dantoine (2002) demonstrated that polymorphisms of PON1 192 appeared to be a reliable 
marker to distinguish patients with AD from patients with VaD, the same study showed no significant 
differences in phenotype distributions among the AD and VaD patients (200). Helbecque studied both AD 
and non-AD demented patients (VaD and mixed dementia) and showed that the R allele was an independent 
risk factor for VaD and mixed dementia (215). A study has indicated that the PON1 gene 192 Q/R 
polymorphism might be associated with greater responsiveness to cholinesterase inhibitors (ChEIs); AD 
patients who responded to ChEIs were observed to have a significantly higher frequency of the R allele than 
non-responders did (P<0.05) (206).   
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On the other hand, our study evaluated the effect of PON1 192Q/R polymorphism on clinical manifestations 
and disease severity in patients with well-defined AD and mixed dementia in a Chinese population. We 
examined dementia subtypes and found that the presence of R allele was significantly associated with 
markedly more neuropsychiatric symptoms and disease severity among patients with mixed dementia, 
whereas no significant differences were found among AD patients. These findings strongly imply an 
interaction of vascular risk factors with PON1 192 Q/R polymorphisms in impacting on clinical 
manifestations and severity presentation of dementia, particularly vascular and mixed dementia. Previous 
studies have extensively investigated the involvement of PON1 192 Q/R polymorphism in coronary artery 
disease (CAD). While some studies indicated that PON1 R allele might be associated with increased CAD 
risk, conflicting results were shown in different studies involving diverse ethnic groups and a heterogeneous 
spread of CAD (198, 253-254). Previous studies by Sanghera on coronary artery disease  (CAD) amongst  
Singaporean Indians and Chinese indicated that the R allele (with decreased paraoxonase activity) was a risk 
factor for CAD among the  Indians but not among the Chinese in Singapore, and found polymorphisms of 
PON2 being associated with CAD instead (257). This inconsistency has been attributed to PON1 192 
polymorphism being in linkage disequilibrium with other closely located functional haplotypes of PON1 and 
PON2 that directly affect CAD. Further studies should investigate the interaction between PON1 
polymorphisms and vascular risk factors in the manifestation of neuropsychiatric symptoms in dementia 
patients.  
 
The study has limitations. First, the sample size of the group of patients with PON1 QQ genotype was small 
(9 QQ in AD group and 9 QQ in mixed dementia group). Although highly significant, the use of multiple 
testing could generate spurious results by chance, hence the results suggesting an effect of PON1 192 Q/R 
polymorphism on neuropsychiatric symptoms manifestations should be replicated in other studies. 
Inadequate control of confounding by vascular and other risk factors especially within the mixed dementia 
patients may also be possible. The influence of other polymorphisms in the PON1 gene and other PON 
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genes on AD and mixed dementia could not be excluded. Other variants could possibly exert protective or 
deleterious effects on dementia risk (201,212). The 161 C/T SNP and rs54565 SNP within intron 1 of PON1 
gene have also been shown to be associated with the risk of developing AD. The study by Erlich (201) 
suggested that low serum paraoxonase activity is a risk factor for AD but the risk is more significantly 
associated with SNPs across all three contiguous genes (PON1, PON2 and PON3) instead  of single 
haplotypes from one gene. Hence the effects of PON activity may be attributed to synergistic activity 
between SNP pairs across the PON cluster instead of a few haplotypes. There is little evidence in this and 
other studies to suggest that ApoE-e4 genotype influenced dementia severity and neuropsychiatric 
symptoms, and sub-analyses did not show an association of APOE with PON1 status, or confounding effect 
on dementia severity and neuropsychiatric symptoms (data not shown). An interaction effect of APOE and 
PON1 is possible, and should be further investigated in future larger studies.   
 
In conclusion, this study yields significant pilot data on PON1 192 Q/R polymorphism and its prevalence 
amongst elderly Singaporean Chinese patients with AD & mixed dementia. Our findings suggest that the 
PON1 gene R allele is predominant and R allele carriers in the mixed dementia group presented with more 
neuropsychiatric symptoms and greater severity of dementia. Further studies between PON gene 
polymorphisms (PON1, PON2, PON3), vascular risk factors and dementia using larger sample sizes and 
involving different ethnic groups will help enhance our understanding of the association and clinical 








   
4.5 Study V 
4.5.1 Results 
The PON1 genotypes were in Hardy-Weinberg equilibrium. Among AD patients (n=87) and age- and sex-
matched controls (n=87), there was no significant difference in the PON1 192 Q/R genotype distribution and 
allele frequencies (Table 15a). In addition, no statistically significant association of PON1 gene 
polymorphism and AD was found between AD patients and controls (Table 16a).  
 
Among non-AD dementia patients (n=66) and age- and sex-matched controls (n=66), a significant difference 
in the PON1 genotype total distribution was observed (29 R/R, 33 Q/R, 4 Q/Q; 32 R/R, 22 Q/R, 12 Q/Q 
respectively, P=0.042); likewise, the presence of at least one R allele was significantly different (93.9 % and 
81.8% respectively, P=0.033) (Table 15b). In conditional logistic regression model, a positive association of 
R alleles carrier status (QR or RR) and non-AD dementia was observed (unadjusted OR=3.67, P=0.046; 
after adjusting for education and APOE ε4 status, OR=3.80, P=0.086); Q/Q genotype was associated with 
lower risk of non-AD dementia (unadjusted OR=0.27, P=0.046; education and APOE ε4 adjusted OR=0.26, 
P=0.086) (Table 16b). 
 
The analyses were stratified by Apolipoprotein E (APOE) allele ε4 status (ε4 carriers/non-carriers). Among 
ε4 non-carriers, there was a significant difference of the presence of at least one R allele (R/R or Q/R) 
between non-AD dementia patients and matched controls (95.6% and 80.0% respectively, P=0.024). R allele 
frequencies was significantly higher in non-AD dementia patients than in controls (72.2% and 52.2% 
respectively, P=0.006) (Table 15b). Conditional regression failed to show a significant association between 
PON1 gene 192Q/R polymorphism and the risk of non-AD dementia in ε4 non-carriers. No significant 
results were observed for APOE ε4 carriers (Table 17b).
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Group No. 
Genotype, n (%) 
P1 P2 P3 
Allele, n (%) 
P4 
RR QR QQ Q R Q/R 





APOE ε4+ 31  19 (61.3) 9 (29.0) 3 (9.7) 0.594 0.688 0.307 20 (32.3) 42 (67.7) 0.476 0.318 
APOE ε4- 56 31 (55.4) 21 (37.5) 4 (7.1) 0.402 0.508 0.109 38 (33.9) 74 (66.1) 0.514 0.189 





APOE ε4+ 31 15 (48.4) 12 (38.7) 4 (12.9)    15 (24.2) 47 (75.8) 0.319  
APOE ε4- 56 24 (42.9) 26 (46.4) 6 (10.7)    29 (25.9) 83 (74.1)  0.349  
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           P1 value for χ2 test of differences in PON1 192Q/R genotype frequencies between AD and control groups.  
          P2 value for χ2 test of differences in (QR + RR) and QQ genotype between AD cases and control groups.  
         P3 value for χ2 test of differences in (QR + QQ) and RR genotype between AD and control groups.  
         P4 value for χ2 test of differences in PON1 allele frequencies between AD and control groups.  
        APOE ε4+: APOE ε2/ε4, ε3/ε4, or ε4/ε4; APOE ε4-: APOE ε2/ ε2, ε2/ε3, or ε3/ ε3. 
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Genotype, n (%) 
P1 P2 P3 
Allele, n (%) 
P4 
RR QR QQ Q R Q/R 





APOE ε4+ 21 7 (33.3) 12 (57.1) 2 (9.5) 0.300 0.634 0.497 16 (38.1) 26 (61.9) 0.615 0.491 
APOE ε4- 45 22 (48.9) 21 (46.7) 2 (4.4) 0.065 0.024 0.833 25 (27.8) 65 (72.2) 0.385 0.006 





APOE ε4+ 21  11 (52.4) 7 (33.3) 3 (14.3)    13 (31.0) 29 (69.0) 0.448  
APOE ε4- 45 21 (46.7) 15 (33.3) 9 (20.0)    43 (47.8) 47 (52.2)  0.915  
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P1 value for χ2 test of differences in PON1 192Q/R genotype frequencies between non-AD and controls.  
P2 value for χ2 test of differences in (QR + RR) and QQ genotype between non-AD and controls.  
P3 value for χ2 test of differences in (QR + QQ) and RR genotype between non-AD and controls.  
P4 value for χ2 test of differences in PON1 allele frequencies between non-AD and controls.  
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                Table 16a Association of PON1 192 Q/R polymorphism and AD  
 
 
 Model 1  Model 2  Model 3 
 OR (95% CI) P value  OR (95% CI) P value  OR (95% CI) P value 
 
R allele carriers 
(RR or QR) 
 
0.67 (0.24-1.87) 0.442  0.80 (0.28-2.32) 0.684  0.84 (0.28-2.51) 0.755 
Q allele carriers 
(QQ or QR) 
 





































   











        
                 Model 1: Unadjusted. 
                Model 2: Adjusted for education. 
                Model 3: Adjusted for education and APOE ε4 status. 
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              Table 16b Association of PON1 gene 192 Q/R polymorphism and non-AD 
 
 
 Model 1  Model 2  Model 3 
 OR (95% CI) P value  OR (95% CI) P value  OR (95% CI) P value 
 
R allele carriers 
(RR or QR) 
 
3.67 (1.02-13.14) 0.046  3.75 (0.84-16.69) 0.083  3.80 (0.83-17.73) 0.086 
Q allele carriers 
(QQ or QR) 
 

















































        
                Model 1: Unadjusted. 
                Model 2: Adjusted for education. 
                Model 3: Adjusted for education and APOE ε4 status.
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Table 17a Association of PON1 192Q/R polymorphism and AD, stratified by APOE ε4 status 
 Model 1  Model 2 
 OR (95% CI) P value  OR (95% CI) P value 
 
AD, APOE ε4+  (n=31) 
    
R allele carriers (RR or QR) 0.75 (0.17-3.35) 0.706  0.76 (0.16-3.45) 0.812 
Q allele carriers (QQ or QR) 1.57 (0.61-4.05) 0.350  1.56 (0.54-4.46) 0.409 
RR 0.64 (0.25-1.64) 0.350  0.64 (0.22-1.84) 0.409 
QR 1.50 (0.53-4.21) 0.442  1.46 (0.45-4.74) 0.525 
QQ 1.33 (0.30-5.96) 0.706  1.32 (0.28-6.24) 0.812 
 
AD, APOE ε4-  (n=56) 
    
R allele carriers (RR or QR) 0.60 (0.14-2.51) 0.484  0.83 (0.19-3.74) 0.81 
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Q allele carriers (QQ or QR) 1.78 (0.79-4.02) 0.167  1.92 (0.80-4.59) 0.144 
RR 0.56 (0.25-1.27) 0.167  0.52 (0.22-1.25) 0.144 
QR 1.50 (0.67-3.34) 0.321  1.86 (0.76-4.55) 0.172 
QQ 1.67 (0.40-6.97) 0.484  1.20 (0.27-5.40) 0.811 
 
Model 1: Unadjusted. Model 2: Adjusted for education. 















   
Table 17b Association of PON1 gene 192 Q/R polymorphism and non-AD, stratified by APOE ε4 status 
 
 Model 1  Model 2 
 OR (95% CI) P value  OR (95% CI) P value 
 
non-AD, APOE ε4+  (n=21) 
    
R allele carriers (RR or QR) 2.00 (0.18-22.06) 0.571  1.24 (0.09-16.26) 0.872 
Q allele carriers (QQ or QR) 2.00 (0.60-6.64) 0.258  1.82 (0.45-7.31) 0.397 
RR 0.50 (0.15-1.66) 0.258  0.55 (0.14-2.20) 0.397 
QR 2.67 (0.71-10.05) 0.147  2.30 (0.47-11.20) 0.303 
QQ 0.50 (0.05-5.51) 0.571  0.81 (0.06-10.63) 0.872 
 
non-AD, APOE ε4-  (n=45) 
    
R allele carriers (RR or QR) 2.99 (0.73-12.36) 0.130  2.44 (0.59-10.11) 0.220 
 92 
   
Q allele carriers (QQ or QR) 0.96 (0.53-1.72) 0.881  1.03 (0.58-1.86) 0.912 
RR 1.05 (0.58-1.88) 0.881  0.97 (0.54-1.74) 0.912 
QR 1.31 (0.73-2.36) 0.363  1.30 (0.73-2.34) 0.377 
QQ 0.33 (0.08-1.38) 0.130  0.41 (0.10-1.70) 0.220 
 
Model 1: Unadjusted. Model 2: Adjusted for education. 
APOE ε4+: APOE ε2/ε4, ε3/ε4, or ε4/ε4; APOE ε4-: APOE ε2/ ε2, ε2/ε3, or ε3/ ε3. 
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4.5.2 Discussion 
The present study showed that the distribution of PON1 192 Q/R genotypes was significantly different 
between non-AD patients and age- and sex- matched controls and these patients showed higher frequency of 
at least one R allele (RR or QR). In particular, the PON1 R allele was significantly more frequent among 
non-AD dementia patients who where APOE ε4 non-carriers. As this case-control study examined the 
association of PON1 192 Q/R gene polymorphism and the risk of dementia in a Singaporean Chinese 
population, it provides useful data for future research. 
 
Among the various subtypes of dementia, AD and VaD are the two most common forms, representing a 
major public health challenge in the world. Both clinical and epidemiological studies suggest that AD and 
VaD share common risk factors and considerable overlap can be found in their pathophysiology, 
symptomatology and comorbidities. In particular, oxidative stress has been well recognized to play an 
important role in the pathogenesis of both diseases (208). 
 
Human paraoxonase 1 (PON1), of which the name is derived from its activity in detoxifying 
organophosphates pesticide, is a component of high-density lipoprotein (HDL) that has antioxidative 
potential. Its ability to protect lipids and low-density lipoprotein (LDL) from oxidation represents a major 
antiatherogenic mechanism. In addition, PON1 has multiple other biological functions, including 
cholinesterase inhibition, arylesterase and lactonase activities. Its enzyme activity is genetically determined 
by a common polymorphism on the position 192 in the PON1 gene. Individuals carrying Arg at position 192 
(R allele) have a higher PON1 serum activity than those carrying Glu (Q allele) (203).   
 
To date, two of ten studies which examined the association of PON1 192 Q/R gene polymorphism and AD 
reported a protective effect of PON1 gene. In a Chinese Han ethnic population, He et al. (2006) found the 
total distribution of PON1 192 Q/R genotypes was not significantly different between AD patients and 
 94 
   
controls (90 QQ, 230 QR, 201 RR and 73 QQ, 262 QR and 243 RR respectively; P=0.09). But they found 
that the presence of at least one R allele (QR or RR) was significantly lower in AD patients than in the age-
matched controls (82.7% vs 87.4%, P=0.03) and the R allele frequency was significantly lower in AD 
patients than in the controls (60.7% and 64.7%, P=0.05). Among the R allele carriers, the age and sex-
adjusted odds ratio (OR) for the risk of AD was 0.71 (95% CI 0.51-0.99, P=0.044) (52). However, in the 
present study, there was no significantly difference of the PON1 192 Q/R genotype distribution and allele 
frequency between AD patients and controls, and no significantly association of PON1 gene 192 Q/R 
polymorphism and the risk of developing AD was observed. However, our findings still confirmed the 
predominance of R allele in the Singaporean Chinese population (AD: 50 RR, 30 QR, 7 QQ; Controls: 39 
RR, 38 QR, 10 QQ), which is consistent with the findings from the case-control study by He et al (52). This 
similarity could be explained by the fact that the Chinese Singaporeans are descendants of Han immigrants 
who migrated to Singapore in the early 19
th
 century from the Southern provinces of China.  
 
On the other hand, few studies have examined the relationship between PON1 gene 192 Q/R polymorphism 
and the risk of non-AD, and the results have been controversial. In the current study, we found a significant 
difference of PON1 gene 192 Q/R genotype distribution (29 RR, 33 QR, 4 QQ; 32 RR, 22 QR, 12 QQ 
respectively, P=0.042) and R allele frequency (93.9% and 81.8% respectively, P=0.033) between non-AD 
patients and gender- matched controls. In particular, the non-AD patients who were APOE ε4 non-carriers 
had significantly  higher frequency of R allele as compared with those patients with at least one ε4 allele 
(72.2% and 52.2% respectively, P=0.006). No significant association of R allele with the risk of developing 
non-AD dementia was found in this study after controlling for education and APOE ε4 status (P=0.086). To 
some extent, our findings are in accordance with what Helbecque et al. reported in 2004. They conducted a 
case-control study with 229 demented patients and 253 controls in a French population and found that the 
PON1 gene R allele was an independent risk factor for non-AD dementia (VaD and mixed dementia), 
particularly in APOE ε4 non-carriers (OR=1.8, 95% CI=1.1-2.9, P=0.02). The preliminary findings 
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suggested that PON1 might play a role in developing non-AD dementia, although the underlying mechanism 
is not completely clarified. As mentioned earlier, PON1 inhibits LDL peroxidation and numerous studies 
suggest that PON1 is associated with cardiovascular diseases, which have been confirmed as risk factors for 
VaD. 
 
The study has limitations. First, the sample size is of the subjects with QQ genotype was small (7 QQ in AD 
patients and 10 QQ in matched controls, and 4 QQ in non-AD patients and 12 QQ in matched controls). 
Future studies should recruit more cases and controls to guarantee a larger test power and provide more 
convincing evidence. Second, as a case-control study, survival bias cannot be excluded from the demented 
patients. Third, the ethnic diversity should also be considered. Singapore is a multi-racial society consisting 
of Chinese, Malays, Indians and Eurasians. However, the current study only included Chinese demented 
patients and matched controls. As ethnic variability may contribute to the difference of genotype distribution 
among demented patients and controls, studies with subjects of other ethnicity are necessarily required in the 
future. Fourth, PON1 serum concentration and activity were not measured in this study. PON1 activity has 
been reported to be lower in VaD than AD (200) indicating that PON1a may discriminate VaD from AD. 
Therefore, future studies with both PON1 gene polymorphism and PON1 activity would provide more 
useful data. Finally, other SNPs of the PON1 gene might also be associated with the risk of developing AD 
(212). Chapuis et al. found that the rs854565 (intron1) was associated with the risk of AD in a French 
population.  Thus, the influence of multi SNPs at the PON1 loci should be considered in future research. 
 
In conclusion, we found that in Singaporean Chinese, the PON1 192Q/R genotype distribution was 
significantly different between non-AD dementia patients and controls and these patients showed greater 
frequency of at least one R allele (R/R or Q/R). In particular, the PON1 R allele was significantly more 
frequent among non-AD dementia patients who were APOE ε4 non-carriers. However, we did not find a 
significant association between PON1 192Q/R gene polymorphism and AD/non-AD dementia. Case-control 
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studies with large sample size and different ethnic groups should be conducted to confirm the association of 

























   
CHAPTER 5 SUMMARY AND CONCLUSION 
This thesis is comprised of five studies with participants from the Singapore Longitudinal Aging Study 
(SLAS) and dementia patients from the Memory Clinic of the Department of Geriatric Medicine in the 
Alexandra Hospital, Singapore. It examined the relationship between APOE ε4 allele status, PON1 gene 192 
Q/R polymorphism and n-3 PUFA and cognition (including cognitive performance, cognitive decline and 
dementia) among Singaporean Chinese older adults (aged 55 and above). 
 
Study I examined the association between omega-3 PUFA supplements intake and cognitive decline in 1475 
participants from SLAS, a prospective cohort study of community-dwelling elderly Chinese Singaporeans. 
The results showed that compared with those who consumed n-3 PUFA less than daily, the participants with 
daily n-3 PUFA supplements intake had significantly lower risk of developing cognitive decline (adjusted 
OR=0.23, 95% C.I. 0.07-0.75, P=0.015) after controlling for possible confounders, which include age, 
gender, education, number of medical comorbidity, hypertension, diabetes, cardiac diseases, stroke, smoking, 
alcohol drinking, depression, APOE ε4 status, nutritional status, level of leisure activity, baseline MMSE, 
length of follow-up, and after excluding participants with cognitive impairment (MMSE <24) at baseline 
and those with diabetes, stroke, and cardiac diseases. However, no statistical significant association of fish 
consumption (3 or more times a week) with cognitive decline was observed in this study (OR=1.02, 95% CI 
0.81-1.27). The data in this observational study supports the suggestion that daily consumption of omega-3 
polyunsaturated fatty acid supplements may be beneficial in preventing cognitive decline in individuals 
without dementia. However, data from more prospective and interventional studies with larger sample size 
and more accurate measurements should provide firmer evidence to support the use of n3-PUFA’s in 
slowing cognitive decline in elderly persons.   
 
Study II investigated the cross-sectional association between omega-3 PUFA supplements intake and 
cognitive performance among non-demented elderly Singaporean Chinese. A total of 710 SLAS-1 
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participants were selected for the study. Both MMSE and a comprehensive battery of neuropsychological 
tests were used to assess cognitive performance. The findings showed that omega-3 supplements daily 
intake was significantly associated with better performance on cognitive domains of memory (β=0.098, 
SE=0.31, P=0.006), executive function (β=0.071, SE=0.43, P=0.046) and information processing speed 
(β=0.074, SE=0.24, P=0.036). In conclusion, our findings suggest that daily consumption of omega-3 
supplements could be possibly preventative for cognitive decline and dementia. This should be more clearly 
established in future longitudinal study with larger sample size and information on dosage and duration of 
omega-3 supplements intake to establish dose-dependent causal relationship. 
 
Study III examined the association between APOE ε4 allele status and dementia in a Chinese Singaporean 
population. It was a case-control design with 153 demented patients (87 AD, 19 VaD and 47 mixed 
dementia) from the Memory Clinic of the Department of Geriatric Medicine in the Alexandra Hospital, 
Singapore and 153 age- and gender-matched cognitively intact controls from the Singapore Longitudinal 
Aging Study-1 (SLAS-1). The results showed that the prevalence of at least one APOE ε4 allele was 
significantly higher in AD patients than in controls (35.6% and 17.2% respectively, P=0.004) and APOE ε4 
carriers had a higher risk of developing AD (adjusted OR=2.41, 95% CI 1.10-5.28, P=0.01). However, such 
association was not found among non-AD demented patients. This study demonstrated that although 
associated with AD among Singaporean Chinese population, the effect of APOE ε4 in increasing the risk of 
AD was not as strong as that observed in the Western populations. No significant association was observed 
with non-AD dementia. In conclusion, this case-control study suggests that although associated with AD 
among Singaporean Chinese, the effect of APOE ε4 in increasing the risk of AD was not strong as that 
observed in Western populations. No significant association was observed with non-AD dementia. More 
studies using larger sample sizes on Chinese, Malays and Indians are warranted to confirm the findings. 
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Study IV, a cross-sectional study, examined the profile of PON1 192 Q/R gene polymorphism and its 
correlations with clinical manifestation and the severity of dementia among 186 patients with dementia (109 
AD and 77 mixed dementia), who attended the Memory Disorders Clinic at Alexandra hospital, Singapore. 
The results showed that both the PON1 192 Q/R genotypes and its allele frequencies were not significantly 
different between AD patients and patients with mixed dementia. However, compared with R allele non-
carriers, R allele carriers showed higher mean NPI-Q (S) and NPI-Q (CD) scores (8.80 versus 4.89, P=0.004; 
8.92 versus 3.94, P=0.002, respectively) in the overall study population. Furthermore, in the mixed dementia 
subgroup, the presence of R allele was significantly associated with higher mean NPI-Q (S) (9.01 versus 
3.11, P=0.039) and NPI-Q (CD) scores (9.09 versus 2.33, P=0.006) as well as higher CDR (SOB) score 
(8.57 versus 5.89, P=0.042), GDS/FAST score (4.84 versus 4.11, P=0.007) and BADL score (6.99 versus 
1.00, P<0.001). This study provides significant preliminary data on the prevalence of PON1 192 Q/R 
polymorphism in Singaporean Chinese patients with AD and mixed dementia, and it also suggests that R 
allele might possibly affect the neuropsychiatric symptoms and clinical manifestations of mixed dementia, 
but not AD. Future studies with larger sample size and including other ethnic groups will help further our 
understanding of the association and clinical significance of PON1 and dementia in Singapore. 
 
Study V examined the association between PON1 gene 192 Q/R polymorphism and the risk of developing 
dementia in a Chinese Singaporean population. A total of 153 demented patients (87 AD, 19 VaD and 47 
mixed dementia) and 153 age- and gender-matched controls were recruited for this study, from the Memory 
Clinic of the Department of Geriatric Medicine in the Alexandra Hospital and the Singapore Longitudinal 
Aging Study-1 (SLAS-1), respectively. The results showed that the PON1 gene 192 Q/R genotype 
distribution was significantly different between the non-AD patients and controls (P=0.042) and these 
patients had a significantly higher frequency of R allele (93.9% and 81.8% respectively, P=0.033). R allele 
was also found to be associated with the risk of non-AD, but this association was not significant after 
controlling for education (unadjusted OR=3.67, P=0.046; adjusted OR=3.80, P=0.086). Moreover, those 
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non-AD patients with the absence of APOE ε4 allele showed significantly greater frequency of PON1 R 
allele. In conclusion, we found that in Singaporean Chinese, the PON1 192Q/R genotype distribution was 
significantly different between non-AD dementia patients and controls and these patients showed greater 
frequency of at least one R allele (R/R or Q/R). In particular, the PON1 R allele was significantly more 
frequent among non-AD dementia patients who were APOE ε4 non-carriers. However, we did not find a 
significant association between PON1 192Q/R gene polymorphism and AD/non-AD dementia. Case-control 
studies with large sample size and different ethnic groups should be conducted to confirm the association of 
PON1 gene polymorphism and dementia subtypes. 
 
These five studies indicated that multiple risk and protective factors related to lipid metabolism are involved 
in cognitive decline and dementia. The complex relationships between lipid related factors, cognitive decline 
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